Motif Bio 20-F 10 Apr 18 2017 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2017shares
Document and Entity Information
Entity Registrant Name	Motif Bio plc
Entity Central Index Key	1,674,657
Document Type	20-F
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	263,519,128
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY

Consolidated statements of comp

Consolidated statements of comprehensive loss - USD ($)		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Continuing operations
General and administrative expenses		$ (8,541,396)	$ (4,912,150)	$ (3,577,180)
Research and development expenses		(29,475,293)	(34,794,815)	(4,680,940)
Gains on settlement of contract disputes			83,320	5,027
Operating loss		(38,016,689)	(39,623,645)	(8,253,093)
Interest income		133,612	69,754	15,028
Interest expense		(275,449)	(383,259)	(268,216)
Net foreign exchange losses		(238,289)	(250,926)	(9,644)
Loss from revaluation of derivative liabilities		(6,391,551)	(135,939)
Loss before income taxes		(44,788,366)	(40,324,015)	(8,515,925)
Income tax expense		(22,000)	(287)	(774)
Net loss for the year		(44,810,366)	(40,324,302)	(8,516,699)
Total comprehensive loss for the year		$ (44,810,366)	$ (40,324,302)	$ (8,516,699)
Net loss per share
Basic and diluted per share	[1]	$ (0.19)	$ (0.35)	$ (0.14)
Weighted average number of ordinary shares, basic and diluted		231,530,091	116,558,191	61,225,922
[1]	In accordance with IAS 33 “Earnings per share”, shares are not diluted where the entity has reported a loss for the period.

Consolidated statements of fina

Consolidated statements of financial position - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Non-current assets
Intangible assets	$ 6,195,748	$ 6,195,748
Other non-current assets	23,075
Total non-current assets	6,218,823	6,195,748
Current assets
Prepaid expenses and other receivables	317,584	401,064
Cash	22,651,475	21,829,632
Total current assets	22,969,059	22,230,696
Total assets	29,187,882	28,426,444
Non-current liabilities
Term loan, net of deferred financing costs	14,057,147
Other non-current liabilities	22,758
Total non-current liabilities	14,079,905
Current liabilities
Trade and other payables	10,889,554	12,319,117
Payable on completion of clinical trial	500,000	500,000
Derivative liabilities	12,626,299	5,798,058
Total current liabilities	24,015,853	18,617,175
Total liabilities	38,095,758	18,617,175
Net (liabilities) assets	(8,907,876)	9,809,269
EQUITY
Share capital	3,589,201	2,728,199
Share premium	80,872,838	57,348,694
Group reorganization reserve	9,938,362	9,938,362
Accumulated deficit	(103,308,277)	(60,205,986)
Total (deficit) equity	$ (8,907,876)	$ 9,809,269

Consolidated statements of chan

Consolidated statements of changes in equity - USD ($)	Share capital	Share premium	Group reorganization reserve	Accumulated deficit	Total
Beginning balance at Dec. 31, 2014	$ 1,110	$ 3,964,455		$ (14,884,023)	$ (10,918,458)
Loss for the year				(8,516,699)	(8,516,699)
Total comprehensive loss for the year				(8,516,699)	(8,516,699)
Conversion of promissory notes	3,573	6,275,213			6,278,786
Group reorganization	539,267	(10,239,668)	$ 9,938,362		237,961
Issue of share capital	1,095,805	41,334,240			42,430,045
Cost of issuance		(2,898,693)			(2,898,693)
Exercise of share options and warrants	5,536	98,733			104,269
Issue of warrants to acquire assets				2,340,373	2,340,373
Share-based payments				665,124	665,124
Ending balance at Dec. 31, 2015	1,645,291	38,534,280	9,938,362	(20,395,225)	29,722,708
Loss for the year				(40,324,302)	(40,324,302)
Total comprehensive loss for the year				(40,324,302)	(40,324,302)
Conversion of promissory notes	177,786	3,373,000			3,550,786
Issue of share capital	897,812	18,701,566			19,599,378
Cost of issuance		(3,370,155)			(3,370,155)
Exercise of share options and warrants	7,310	110,003			117,313
Share-based payments				513,541	513,541
Ending balance at Dec. 31, 2016	2,728,199	57,348,694	9,938,362	(60,205,986)	9,809,269
Loss for the year				(44,810,366)	(44,810,366)
Total comprehensive loss for the year				(44,810,366)	(44,810,366)
Issue of share capital	846,667	24,569,634			25,416,301
Cost of issuance		(1,734,562)			(1,734,562)
Exercise of share options and warrants	14,335	689,072			703,407
Share-based payments				1,708,075	1,708,075
Ending balance at Dec. 31, 2017	$ 3,589,201	$ 80,872,838	$ 9,938,362	$ (103,308,277)	$ (8,907,876)

Consolidated statements of cash

Consolidated statements of cash flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating activities
Operating loss for the year	$ (38,016,689)	$ (39,623,645)	$ (8,253,093)
Adjustments to reconcile net loss to net cash used in activities:
Share-based payments	1,708,075	513,541	325,908
Warrant issued for services performed	109,431
Gain on settlement of contract disputes		(83,320)	(5,027)
Interest receivable	133,612	69,754	15,028
Taxation payable		(287)	(774)
Changes in operating assets and liabilities:
Prepaid expenses and other receivables	60,405	(233,407)	(155,578)
Accounts payable and other accrued liabilities	(1,429,563)	11,415,353	75,852
Net cash used in operating activities	(37,434,729)	(27,942,011)	(7,997,684)
Financing activities
Proceeds from issuance of promissory notes			704,210
Proceeds from issuance of term loan	15,000,000
Costs of issuance of term loan	(575,970)
Proceeds from issue of share capital	25,416,301	24,995,980	38,660,106
Costs of issuance of share capital	(1,734,562)	(3,370,155)	(2,559,477)
Proceeds from exercise of warrants and options	419,004	117,313	62,739
Interest paid	(70,833)	(314,916)	(268,216)
Net cash provided by financing activities	38,453,940	21,428,222	36,599,362
Net change in cash	1,019,211	(6,513,789)	28,601,678
Cash, beginning of the year	21,829,632	28,594,347
Effect of foreign exchange rate changes	(197,368)	(250,926)	(10,612)
Cash, end of the year	22,651,475	21,829,632	28,594,347
Non-cash investment activity
Acquisition of intangible asset with equity issuances			$ 6,195,748
Non-cash financing activity
Conversion of notes payable to ordinary shares		3,550,786
Fair value of warrants issued in conjunction with issuance of share capital		$ 5,662,119
Fair value of warrants issued in conjunction with issuance of term loan	$ 419,573

General information

General information	12 Months Ended
	Dec. 31, 2017
General information
General information	1. General information Motif Bio plc is a clinical stage biopharmaceutical company which specializes in developing and commercializing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Motif Bio Limited (“the Company”) was incorporated in England and Wales on November 20, 2014 with company registration number 09320890. The Company’s registered office is at: 201 Temple Chambers, 3-7 Temple Avenue, London EC4Y 0DT, U.K. On April 1, 2015, the Company was re-registered as a public company limited by shares and changed its name to Motif Bio plc. Motif BioSciences Inc. was incorporated in the US State of Delaware on December 2, 2003 and has its registered office at 251 Little Falls Drive, Wilmington, Delaware, 19808. On April 1, 2015, Motif BioSciences Inc. became a wholly owned subsidiary of the Company by way of a group reorganization by plan of merger. The principal place of business is 125 Park Avenue, 25 th Floor, New York, NY, 10017, USA. The Company’s country of domicile is the U.K. The consolidated financial statements include the accounts of Motif Bio plc and its wholly owned subsidiary, Motif BioSciences Inc. (“the Group”). The financial statements were approved by the Board of Directors on April 9, 2018. Going concern As of December 31, 2017, the Group had $22.7 million in cash. Net cash used in operating activities was $37.4 million for the year ended December 31, 2017. Net loss for the year ended December 31, 2017 was $44.8 million. The Group expects to incur losses for the next several years as it expands its research, development and clinical trials of iclaprim and prepare for commercialization upon regulatory approval of iclaprim. The Group is unable to predict the extent of any future losses or when the Group will become profitable, if at all. The Group will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. The Group cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Group raises additional funds by issuing equity securities, its stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Group’s ability to conduct business. If the Group is unable to raise additional capital when required or on acceptable terms, it may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that the Group would otherwise seek to develop or commercialize itself on unfavorable terms. These financial statements have been prepared under the assumption that the Group will continue as a going concern. Due to the Group’s recurring and expected continuing losses from operations, as well as significant amounts of outstanding payables and accrued expenses, the Group has concluded there is substantial doubt in the Group’s ability to continue as a going concern within one year of the issuance of these financial statements without additional capital becoming available. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Significant events On November 15, 2017, the Group entered into a credit agreement (the “Hercules Loan Agreement”) with Hercules Capital, Inc. (“Hercules”). Pursuant to the credit agreement, Hercules agreed to loan the Group $20.0 million in two tranches. The first tranche of $15.0 million was drawn down at closing, with the remaining $5.0 million available upon the achievement of certain milestones anticipated in 2018, or at Hercules’ discretion. The terms include an initial interest-only period of 15 months, extendable to 21 months on the achievement of certain milestones; a 30-month capital and interest repayment period thereafter; an interest rate of 10% tied to the U.S. prime rate and customary security over all assets of the Group, except for intellectual property where there is a negative pledge. Under the Hercules Loan Agreement, the Group issued Hercules a warrant to purchase up to 73,452 of its American Depositary Shares (ADSs) at an exercise price of $9.53 per ADS, representing 3.5% warrant coverage of the total loan facility. Hercules also has the right, in its discretion, to participate in any subsequent financing, such as an equity offering, in an amount up to $1 million. On June 23, 2017, the Group placed 66,666,667 new ordinary shares at 30 pence per share and received $23,681,739 of net proceeds. On November 18, 2016, the Group announced the pricing of the underwritten U.S. offering and European placement, which were concurrently conducted, of 71,633,248 ordinary shares, comprised of 22,863,428 ordinary shares plus 2,438,491 ADSs (representing 48,769,820 ordinary shares at a 20 to 1 ratio). The Group offered 48,769,820 ordinary shares in a U.S. firm commitment offering in the form of 2,438,491 ADSs, together with warrants to purchase 1,219,246 ADS Warrants. Each ADS represents 20 of the Group’s ordinary shares and was sold together with 0.5 of an ADS Warrant in a fixed combination. Each full ADS Warrant is exercisable for one ADS at an exercise price of $8.03 per ADS, exercisable from the date of issuance until five years thereafter. In Europe, the Group offered in a concurrent placement on a best efforts basis 22,863,428 ordinary shares, together with warrants to purchase 11,431,714 ordinary shares. Each ordinary share was sold together with 0.5 of an Ordinary Share Warrant in a fixed combination. Each full Ordinary Share Warrant is exercisable for one ordinary share at an exercise price of £0.32 ($0.40), exercisable from the date of issuance until five years thereafter. The offering price of the ADSs and ADS Warrants in the U.S. offering was $6.98 per ADS and ADS Warrant combination, and the offering price of the Group’s ordinary shares and Ordinary Share Warrants in the European placement was £0.28 ($0.35) per ordinary share and Ordinary Share Warrant combination. Net proceeds to the Group following the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $3.5 million, were approximately $21.5 million. None of the underwriting discounts and commissions or other offering expenses were paid to directors or officers of the Group or their associates or to persons owning 10 percent or more of any class of the Group’s equity securities or to any affiliates of the Group. H.C. Wainwright & Co., LLC was the underwriter for the above described offering. On September 7, 2016, the Group amended and restated the convertible notes with Amphion Innovations plc and Amphion Innovations US Inc. to provide that any outstanding principal under the notes as of the maturity date will be paid to the holders on the maturity date, at the Group’s election, through the issuance of (i) a number of ordinary shares, based on the conversion price set forth in the notes, or (ii) a number of ADSs, which is equal to a number determined by dividing the number of ordinary shares the holder would otherwise be entitled to by the then applicable ADS to ordinary share ratio. The amended and restated convertible promissory notes also provide that except in the event of a default, no interest will accrue or be payable with respect to the amounts due under the notes. In consideration for its agreement to forego interest payments under its convertible promissory notes, the Group issued 409,000 ordinary shares to Amphion Innovations plc. The amended and restated notes also permit the Group or the holders to convert all or any portion of the outstanding principal under the notes into ordinary shares or ADSs (as determined by the Group) at any time prior to the maturity date. In December 2016, the Group issued 14,510,770 new ordinary shares following the conversion of convertible promissory notes by Amphion Innovations plc and Amphion Innovations US Inc. The notes totaled US $3,550,786 and were converted in accordance with their terms at US $0.2447 per share. Group reorganization and initial public offering On February 18, 2015, the Company incorporated a Delaware subsidiary, Motif Acquisition Sub, Inc. On December 31, 2014 Motif BioSciences Inc., the Company, and Motif Acquisition Sub, Inc. entered into an agreement where, upon the Company’s admission to AIM of the London Stock Exchange on April 2, 2015, Motif Acquisition Sub, Inc. merged with and into Motif BioSciences Inc. and Motif BioSciences Inc. continued as the surviving entity and became a wholly-owned subsidiary of the Company. Prior to the merger, Motif BioSciences Inc. completed a reverse stock split in order to increase the share price of Motif BioSciences Inc. so that the share price was closer to the Company’s admission price. The former Motif BioSciences Inc. stockholders were issued 36,726,242 ordinary shares of the Company in a share-for-share exchange for their common stock in Motif BioSciences Inc. so that the former Motif BioSciences Inc. stockholders owned an equivalent number of ordinary shares in the Company as the number of shares of common stock that they had previously owned in Motif BioSciences Inc. All outstanding, unexercised, and vested stock options for shares of common stock in Motif BioSciences Inc. were converted into options for ordinary shares of the Company (Note 16). This was a common control transaction and therefore outside the scope of IFRS 3—“Business Combinations.” The transaction has therefore been accounted for as a group reorganization and the Group is presented as if the Company has always owned Motif BioSciences Inc. The comparatives presented in these financial statements therefore represent the results and capital structure of the Company. The reserve on consolidation represents the difference between the nominal value of the shares of the Company issued to the former stockholders of Motif BioSciences Inc. and the share capital and share premium of Motif BioSciences Inc. at the date of the transaction. As stated, the nominal value of the Company shares was used in the calculation of the reorganization reserve. On April 2, 2015, the Company was admitted to AIM and issued 14,186,140 ordinary shares at a price of £0.20 per share. On July 22, 2015, the Company completed a subsequent placing of 44,000,000 ordinary shares at a price of £0.50 per share. Acquisition of Nuprim Assets On April 1, 2015, Motif BioSciences Inc. acquired the assets owned by Nuprim Inc. (“Nuprim”), a Maryland corporation, related to iclaprim (the “Nuprim Assets”). Motif BioSciences Inc. issued 1,513,040 (post-reverse stock split) shares of common stock to the shareholders of Nuprim. that were held in escrow until the closing of the reorganization. These shares of common stock in Motif BioSciences Inc. were converted into ordinary shares of the Company upon the Company’s admission to AIM on April 2, 2015. Upon admission, 9,805,400 ordinary shares of the Company and 9,432,033 warrants were issued to the former Nuprim shareholders (Note 9).

Significant accounting policies

Significant accounting policies	12 Months Ended
	Dec. 31, 2017
Significant accounting policies
Significant accounting policies	2. Significant accounting policies a. Basis of preparation The accounting policies set out below have been applied consistently to all periods presented in this financial information. The financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and in conformity with IFRS as adopted by the European Union. This basis of preparation describes how the financial statements have been prepared in accordance with IFRS. The financial statements have been prepared under the historical cost convention. A summary of the more important Group accounting policies is set out below. The preparation of financial statements in conformity with IFRS requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial information and the reported amounts of revenue and expenses during the period. Although these estimates are based on management’s best knowledge of the amount, event or actions, actual results ultimately may differ from those estimates. a. New and amended standards effective from January 1, 2017 Amendments to IAS 7, Disclosure Initiative, was adopted with an effective date of January 1, 2017. The amendments require disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities, including both changes arising from cash flow and non-cash changes. The Group believes that the disclosure contained herein adequately satisfy this requirement. The only balance sheet liability for which cash flows are classified as financing activities is the term loan with Hercules Capital, Inc. The cash inflow in the year in respect of the term loan was $14.4 million, net of issuance costs and non-cash movement of $0.4 million for the issuance of warrants. The net movement and resulting closing balance is further detailed in Note 13. There are no other new standards and amendments that have been applied from January 1, 2017, which have had an impact on the Group’s financial statements. New standards and interpretations not yet effective Certain new accounting standards and interpretations have been published that are not mandatory for the reporting periods covered by these consolidated financial statements and have not been early adopted by the Group. The new standards potentially relevant to the Group are discussed below. IFRS 2, Share-based Payments (as amended) — Effective date — January 1, 2018. The Group currently plans to apply IRFS 2 initially on January 1, 2018. IFRS 2 related to the classification and measurement of share-based payment transactions. The amendments are intended to eliminate diversity in practice regarding (i) accounting for cash-settled share-based payment transactions that include a performance condition, (ii) share-based payments in which the manner of settlement is contingent on future events, (iii) share-based payments settled net of tax withholdings, and (iv) modification of share-based payment transactions from cash-settled to equity-settled. Based on the initial assessment, this standard is not expected to have a material impact on the Group. IFRS 9, Financial Instruments (as revised in 2014) — Effective date — January 1, 2018, with early adoption permitted. The Group currently plans to apply IRFS 9 initially on January 1, 2018. IFRS 9 includes revised guidance on the classification and measurement of financial instruments, a new expected credit loss model for calculating impairment on financial assets, and new general hedge accounting requirements. Based on the initial assessment, this standard is not expected to have a material impact on the Group. IFRS 15, Revenue from Contracts with Customers — Effective date — January 1, 2018, with early adoption permitted. — IFRS 15 establishes a comprehensive guideline for determining when to recognize revenue and how much revenue to recognize. The Group currently has no revenues, therefore, the adoption of IFRS 15 is not expected to have a material impact on the Group, however, the Group will continue to reassess the potential impact of the adoption of this guidance. IFRS 16, Leases — Effective date — January 1, 2019 — IFRS 16 will replace IAS 17. It will eliminate the distinction between classification of leases as finance or operating leases for lessees. The adoption of IFRS 16 is not expected to have a significant impact on the Group’s net results or net assets, however, the Group will continue to reassess the potential impact of the adoption of this guidance as the effective date becomes closer. Principles of consolidation Subsidiaries are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases. Intercompany transactions, balances, and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. When the Group ceases to consolidate because of a loss of control, any retained interest in the entity is remeasured to its fair value with the change in carrying amount recognized in profit or loss. This fair value becomes the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate, joint venture, or financial asset. b. Segment reporting The chief operating decision-maker is considered to be the Board of Directors of Motif Bio plc. The chief operating decision-maker allocates resources and assesses performance of the business and other activities at the operating segment level. In addition, they review the IFRS consolidated financial statements. The chief operating decision-maker has determined that Motif has one operating segment to support its strategy for the development and commercialization of pharmaceutical formulations. The Group maintains space and has some activities in the U.K.; however, the finance and most other management functions take place in the U.S. c. Foreign currency translation (a) Functional and Presentation Currency Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The consolidated financial statements are presented in United States Dollars (US $), which is Motif Bio plc’s functional and presentation currency. (b) Transactions and balances Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss. They are deferred in equity if they relate to qualifying cash flow hedges and qualifying net investment hedges or are attributable to part of the net investment in a foreign operation. Foreign exchange gains and losses that relate to borrowings are presented in the statement of profit or loss, within finance costs. All other foreign exchange gains and losses are presented in the statement of profit or loss on a net basis within other income or other expenses. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as available-for-sale financial assets are recognized in other comprehensive income. d. Research and development costs Expenditure on drug development activities is capitalized only if all of the following conditions are met: · it is probable that the asset will create future economic benefits; · the development costs can be measured reliably; · technical feasibility of completing the intangible asset can be demonstrated; · there is the intention to complete the asset and use or sell it; · there is the ability to use or sell the asset; and · adequate technical, financial, and other resources to complete the development and to use or sell the asset are available. These conditions are generally met when a filing is made for regulatory approval for commercial production. Otherwise, costs on research activities are recognized as an expense in the period in which they are incurred. At this time, the Group does not meet all conditions and therefore development costs are recorded as expense in the period in which the cost is incurred. The Group’s preclinical studies and clinical trials have been performed utilizing third-party contract research organizations (“CROs”) and other vendors. For preclinical studies, the significant factors used in estimating accruals include the percentage of work completed to date and contract milestones achieved. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, duration of enrollment, percentage of work completed to date and contract milestones achieved. The Group monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence and status meetings and review of contractual terms. Estimates are dependent on the timeliness and accuracy of data provided by the CROs and other vendors. In this event, the Group could record adjustments to research and development expenses in future periods when the actual activity levels become known. e. Intangible assets Intangible assets acquired separately from a business are initially stated at cost, net of any amortization and any provision for impairment. Where a finite useful life of the acquired intangible asset cannot be determined, the asset is not subject to amortization but is tested for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. f. Impairment of non-financial assets Assets that have an indefinite useful life are not subject to amortization and are tested annually in the second half of each fiscal year for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. g. Financial instruments—initial recognition and subsequent measurement A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. a) Financial assets, initial recognition and measurement All financial assets, such as receivables and deposits, are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. The Group assesses, at each reporting date, whether there is objective evidence that a financial asset or a group of financial assets is impaired. An impairment exists if one or more events that has occurred since the initial recognition of the asset (an incurred “loss event”), has an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated. b) Financial liabilities, initial recognition and measurement Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, and payables, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Company’s financial liabilities include trade and other payables, loans and borrowings and warrants classified as liabilities. c) Subsequent measurement The measurement of financial liabilities depends on their classification. Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial assets at fair value through profit or loss are subsequently carried at fair value. Loans and receivables are subsequently carried at amortized cost using the effective interest method if the time value of money is significant. h. Financial assets and liabilities Financial assets and financial liabilities are included in the Group’s balance sheet when the Group becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the investments have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Non-derivative financial instruments Cash and cash equivalents Cash and cash equivalents include bank balances, demand deposits, and other short-term, highly liquid investments (with less than three months to maturity) that are readily convertible into a known amount of cash and are subject to an insignificant risk of fluctuations in value. Financial liabilities and equity The Group classifies an instrument, or its component parts, on initial recognition as a financial liability or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability and an equity instrument. An instrument is classified as a financial liability when it is either (i) a contractual obligation to deliver cash or another financial asset to another entity; or (ii) a contract that will or may be settled in the Group’s own equity instruments and is a non-derivative for which the Group is, or may be, obliged to deliver a variable number of the Group’s own equity instruments or a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Group’s own equity instruments. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds. An equity instrument is defined as any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. An instrument is an equity instrument only if the issuer has an unconditional right to avoid settlement in cash or another financial asset. Trade payables Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities. Trade payables are initially measured at fair value, and are subsequently measured at amortized cost, using the effective interest rate method. Equity instruments Equity instruments issued by the Company are recorded at the proceeds received. Direct issuance costs are processed as a deduction on equity. Derivative financial instruments The Group does not have a policy of engaging in speculative transactions, nor does it issue or hold financial instruments for trading purposes. The Group has entered into various financing arrangements with its investors, including convertible loans. These convertible loans each include embedded financial derivative elements (being the right to acquire equity in the Group at a future date for a pre-determined price). Therefore, while the Group does not engage in speculative trading of derivative financial instruments, it may hold such instruments from time to time as part of its financing arrangements. The Group has also entered into financing arrangements that include the issuance of warrants. These warrants may be considered derivative financial instruments based on the terms of the agreements. Derivatives are initially recognized at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. The resulting gain or loss is recognized in the consolidated income statement, as the Group currently does not apply hedge accounting. Impairment of financial assets The Group assesses at the end of each reporting period whether there is objective evidence that a financial asset or group of financial assets is impaired. A financial asset or a group of financial assets is impaired and impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a “loss event”) and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated. Evidence of impairment may include indications that the debtors or a group of debtors is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization, and where observable data indicate that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or economic conditions that correlate with defaults. For loans and receivables category, the amount of the loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset’s original effective interest rate. The carrying amount of the asset is reduced and the amount of the loss is recognized in the consolidated income statement. If a loan or held-to-maturity investment has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. As a practical expedient, the Group may measure impairment on the basis of an instrument’s fair value using an observable market price. If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized (such as an improvement in the debtor’s credit rating), the reversal of the previously recognized impairment loss is recognized in the consolidated income statement. i. Offsetting financial instruments Financial assets and liabilities are offset and the net amount is reported in the balance sheet when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency, or bankruptcy of the Company or the counterparty. j. Share-based payment transactions The fair value of options and warrants granted to employees, directors, and consultants is recognized as an expense, with a corresponding increase in equity, over the period in which the option and warrant holders become unconditionally entitled to the options and warrants unless incremental and directly attributable to an equity transaction in which case it is deducted from equity. The fair value of the options and warrants granted is measured using an option valuation model, taking into account the terms and conditions upon which the options were granted. k . Financial income and expenses Financial income comprises interest receivable on funds invested. Financial expenses comprise interest payable. Interest income and interest payable are recognized in the income statement as they accrue, using the effective interest method. l . Taxation Tax on the profit or loss for the year comprises current and deferred tax. Tax is recognized in the income statement except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantively enacted at the balance sheet date and any adjustment to tax payable in respect of previous years. Deferred tax is provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: the initial recognition of goodwill; the initial recognition of assets or liabilities that affect neither accounting nor taxable profit other than in a business combination; and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. m. Earnings per share The Company presents basic and diluted earnings per share (EPS) data for its shares. Basic EPS is calculated by dividing the profit or loss attributable to shares of the Company by the weighted average number of shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to shareholders and the weighted average number of shares outstanding for the effects of all dilutive potential shares, which comprise share options and warrants granted to employees and non-employees. In periods when the Company has a loss attributable to shareholders, diluted EPS equates to basic EPS. n. Borrowings Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method. o. Equity The Company classifies an instrument, or its component parts, on initial recognition as a financial liability or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability and an equity instrument. An instrument is classified as a financial liability when it is either (i) a contractual obligation to deliver cash or another financial asset to another entity; or (ii) a contract that will, or may be, settled in the Company’s own equity instruments and is a non-derivative for which the Company is, or may be, obliged to deliver a variable number of the Company’s own equity instruments or a derivative that will or may be settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company’s own equity instruments. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds. An equity instrument is defined as any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. An instrument is an equity instrument only if the issuer has an unconditional right to avoid settlement in cash or another financial asset. Ordinary Shares Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction from the proceeds p. Critical accounting estimates and judgments In preparing the financial information, the Directors make judgments on how to apply the Group’s accounting policies and make estimates about the future. The critical judgments that have been made in arriving at the amounts recognized in the financial information and the key sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying value of assets and liabilities in the next financial year, are discussed below: Acquisition and valuation of the iclaprim assets The directors, on assessing if the acquisition of the Nuprim iclaprim assets was of a business or of a group of assets, considered: · the identified elements of the acquired group; · the capability of the acquired group to produce outputs; and · the impact that any missing elements have on a market participant’s ability to produce outputs with the acquired group. As the acquired group was not accompanied by any associated processes and because the acquired assets do not have planned principal activities, or a plan to produce outputs, the Directors considered the acquisition to be of a group of assets, not a business. The Directors use their judgment to identify the separate intangible assets and then determine a fair value for each based upon the consideration paid, the nature of the asset, industry statistics, future potential, and other relevant factors. Asset acquisitions are measured based on their cost to the acquiring entity, which generally includes transaction costs. An asset’s acquisition cost or the consideration transferred by the acquiring entity is assumed to be equal to the fair value of the net assets acquired, unless contrary evidence exists. These fair values are tested for impairment annually. Research and development expenditures Research and development expenditures are currently not capitalized because the criteria for capitalization are not met. At each balance sheet date, the Group estimates the level of service performed by the vendors and the associated costs incurred for the services performed. Although the Group does not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period. Share based payments and fair value of warrants The Directors have to make judgments when deciding on the variables to apply in arriving at an appropriate valuation of share based compensation and warrants, including appropriate factors for volatility, risk free interest rate, and applicable future performance conditions and exercise patterns.

Financial risk management

Financial risk management	12 Months Ended
	Dec. 31, 2017
Financial risk management
Financial risk management	3. Financial risk management This note explains the Group’s exposure to financial risks and how these risks could affect the Group’s future financial performance. a. Credit risk Credit risk arises from cash and cash equivalents, deposits with banks and financial institutions, and if a counterparty will default on its contractual obligations resulting in financial loss to the Group. The credit risk on liquid funds is limited because cash balances are held with bank and financial institutions with credit-ratings assigned by international credit-rating agencies. All deposits are held with banks with S&P ratings of A-2 and AA- for short term deposits. At December 31, 2017, no current asset receivables were aged over three months. No receivables were impaired. b. Liquidity risk Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they become due. The principal risk to which the Group is exposed is liquidity risk. See discussion in Note 1 as it relates to the Group’s ability to continue as a going concern. The Group has financed its operations to date using cash raised through the issuance of debt and equity. The Directors acknowledge that uncertainty remains over the ability of the Group to have the resources to fully support advancing iclaprim through regulatory approval and commercialization in the United States and Europe. Subject to the availability of funding, the Group also plans to commence additional phase 3 clinical trials of iclaprim in patients with hospital acquired bacterial pneumonia, including those with ventilator-associated bacterial pneumonia. To fund the additional clinical trial and the commercialization of iclaprim, the Group will need additional funding through public markets, private financing, and/or partnering opportunities. The Group is heavily dependent on the public markets both in the United States and United Kingdom. A downturn in the public markets, especially in biotech, may make it difficult for the Group to obtain sufficient funds on acceptable terms. A delay obtaining additional funding could lead to a decrease in the Group’s prospects for the commercialization of iclaprim. In the event that the Group does not have adequate capital to maintain or develop its business, additional capital may not be available to the Group on a timely basis, on favorable terms, or at all, which could have a material and negative impact on the Group’s business and results of operations. Contractual maturities of financial liabilities: Between 1 Between 2 < 1 year and 2 years and 5 years Over 5 years At December 31, 2017 US $ US $ US $ US $ Total Trade and other payables — — — Payable on completion of clinical trial — — — Derivative liabilities — — — Term Loan and other non-current (Note 13) — — — Between 1 Between 2 < 1 year and 2 years and 5 years Over 5 years At December 31, 2016 US $ US $ US $ US $ Total Trade and other payables — — — Payable on completion of clinical trial — — — Derivative liabilities — — — — — c. Market risk Foreign currency risk The Group undertakes certain transactions denominated in foreign currencies. Hence, exposures to exchange rate fluctuations arise. Exchange rate exposures are managed by minimizing the balance of foreign currencies to cover expected cash flows during periods where there is strengthening in the value of the foreign currency. The Group holds part of its cash resources in US dollars and British pounds sterling. The valuation of the cash fluctuates along with the US dollar/sterling exchange rate. No hedging of this risk is undertaken. The carrying amounts of foreign currency denominated monetary net assets at the reporting date are as follows: December 31, 2017 December 31, 2016 US $ US $ Sterling - Cash At December 31, 2017, a change in foreign currency exchange rates is not expected to have a significant impact on the profit or losses of the Group. Interest rate risk The Group’s exposure to interest rate risk is limited to interest earned on the cash and cash equivalent balance of $22.7 million and its financing exposures on the Hercules loan, which has an initial interest rate of 10% tied to the U.S. prime rate. A change in interest rates is not expected to have a significant impact on the profit or losses of the Group. d. Capital risk management The Directors define capital as the total equity of the Group. The Directors’ objectives when managing capital are to safeguard the Group’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal structure to reduce the cost of capital. In order to maintain an optimal capital structure, the Directors may adjust the amount of dividends paid to shareholders, return capital to shareholders and issue new shares to reduce debt.

Other income and expense items

Other income and expense items	12 Months Ended
	Dec. 31, 2017
Other income and expense items
Other income and expense items	4. Other income and expense items This note provides a breakdown of the items included in other income, finance income, and costs and an analysis of expenses by nature for the years ended December 31, 2017, 2016 and 2015. a. Other income Year ended Dec Year ended Dec Year ended Dec US $ US $ US $ Gains on settlement of contract disputes — The gain on settlement of contract disputes for the year ended December 31, 2016 relates to a write off of a payable due to a consultant as a result of a settlement with him. The gain on settlement of contract disputes for the year ended December 31, 2015 primarily relates to payables to a Director for amounts owed to him for his services as Chief Executive Officer. These amounts were written off in a settlement agreement. b. Breakdown of expenses by nature Year ended Dec Year ended Dec Year ended Dec US $ US $ US $ General and administrative expenses Employee benefits expenses, including share-based payments Directors’ fees Legal and professional fees Investor and public relations advisory fees Other expenses Research and development costs Employee benefits expenses, including share-based payments — Contract research organization expenses Chemistry and manufacturing development and other non-clinical development Other research and development costs 2017 2016 2015 Auditors’ Remuneration US $ US $ US $ Audit Fees Audit-Related Fees — — — Tax Fees — — — Other Fees — — — Total c. Finance income and costs Year ended Dec Year ended Dec Year ended Dec US $ US $ US $ Finance income Interest from financial assets Finance costs Interest expense ) ) ) Accretion of end of term payment ) — — Amortization of deferred financing costs ) — — ) ) ) Net finance costs ) ) )

Employee numbers and costs

Employee numbers and costs	12 Months Ended
	Dec. 31, 2017
Employee numbers and costs
Employee numbers and costs	5. Employee numbers and costs The monthly average number of persons employed by the Group (including Executive Directors but excluding Non-executive Directors) and key management personnel during the year, analyzed by category, was as follows: Year ended Year ended Year ended Executive Directors Key management personnel Total The aggregate payroll costs of Executive Directors and key management personnel were as follows: Year ended Year ended Year ended US $ US $ US $ Short term benefits: Wages and salaries Social security and other employer costs Share based payments(1) (1) The total share based payments does not reflect the out-of-period adjustment recorded in 2017 (Note 16).

Directors' remuneration

Directors' remuneration	12 Months Ended
	Dec. 31, 2017
Directors' remuneration
Directors' remuneration	6. Directors’ remuneration Salaries Social 2017 2016 2015 and fees Bonuses Security Total Total Total US $ US $ US $ US $ (2) US $ US $ Executive Graham Lumsden(1)(2) Non-executive Robert Bertoldi(2) — Richard Morgan — — Charlotta Ginman(3) — — Jonathan Gold — — Zaki Hosny — — Mary Lake Polan — — John Stakes(4) — — — — Bruce Williams — — Craig T. Albanese — — — — Total (1) On February 28, 2018, Dr. Lumsden was awarded a cash bonus of $127,500 for services provided in 2017. A portion, or $42,500, of the cash bonus is contingent on meeting certain operational milestones in 2018. (2) Total remuneration for Dr. Lumsden and Mr. Bertoldi exclude employer 401k pension contributions of $7,950 and $6,075, respectively, during 2017. (3) Ms. Ginman’s remuneration for 2017 was £52,195 or US $67,279 based on an average exchange rate of 1.289 for the period. (4) Mr. Stakes resigned from the Board of Directors effective July 1, 2016. The Directors’ remuneration included in the table above represents the amount paid and/or awarded to each director during the years ending December 31, 2017 and 2016. The highest paid director’s aggregate emolument was $567,999 for the year ending December 31, 2017. No director exercised share options during the year ending December 31, 2017. Directors of the Company have been awarded rights to subscribe for shares in the Group as set out below. Exercise January 1, December 31, price Grant Expiry 2017 Granted 2017 US $ date date Richard Morgan — $ Jan 1, 2010 Jan 1, 2020 — $ Jan 1, 2011 Jan 1, 2021 — Dec 4, 2014 Dec 4, 2024 — Craig T. Albanese — $ May 4, 2017 May 4, 2027 — Robert Bertoldi — $ Jan 1, 2010 Jan 1, 2020 — $ Dec 4, 2014 Dec 4, 2024 — Charlotta Ginman — $ Dec 4, 2014 Dec 4, 2024 — Jonathan Gold — $ Jan 1, 2010 Jan 1, 2020 — $ Jan 1, 2011 Jan 1, 2021 — $ Dec 4, 2014 Dec 4, 2024 — Zaki Hosny — $ Jun 18, 2009 Jun 18, 2019 — $ Jan 1, 2010 Jan 1, 2020 — $ Jan 1, 2011 Jan 1, 2021 — $ Jan 30, 2013 Jan 30, 2023 — $ Dec 4, 2014 Dec 4, 2024 — Graham Lumsden — $ May 25, 2013 May 25, 2023 — $ Dec 4, 2014 Dec 4, 2024 — $ Feb 7, 2017 Feb 7, 2027 — $ Feb 7, 2017 Feb 7, 2027 Mary Lake Polan — $ Jan 1, 2010 Jan 1, 2020 — $ Jan 1, 2011 Jan 1, 2021 — $ Dec 4, 2014 Dec 4, 2024 — Bruce Williams — $ Jan 1, 2010 Jan 1, 2020 — $ Jan 16, 2010 Jan 16, 2020 — $ Nov 15, 2010 Jan 16, 2020 — $ Jan 1, 2011 Jan 1, 2021 — $ Dec 4, 2014 Dec 4, 2024 —

Income tax expense

Income tax expense	12 Months Ended
	Dec. 31, 2017
Income tax expense
Income tax expense	7. Income tax expense Recognized in the income statement: Year Year ended Year ended Current tax expense US $ US $ US $ U.K. corporation taxes — — — Overseas taxes The main rate of U.K. corporation tax was reduced from 21% to 19% from April 1, 2015 and has been reflected in these consolidated financial statements. The tax expense recognized for the years ended December 31, 2017, 2016 and 2015 is lower than the standard rate of corporation tax in the U.K. of 19%. The differences are reconciled below: 2017 2016 2015 Reconciliation of effective tax rate: US $ US $ US $ Loss on ordinary activities before taxation ) ) ) U.K. Corporation tax at 19% ) ) ) Overseas tax at higher rate ) ) ) Effects of: Unrecognized losses ) ) ) Other adjustments-overseas taxes Total tax charge There is an unrecognized cumulative deferred tax asset of US$1,783,102, relating to deferred tax on losses generated of US$10,488,833, in the U.K. during the years ended December 31, 2017 and 2016.

Loss per share

Loss per share	12 Months Ended
	Dec. 31, 2017
Loss per share
Loss per share	8. Loss per share Basic loss per share is calculated by dividing the loss attributable to equity holders of the Group by the weighted average number of shares in issue during the year. In accordance with IAS 33, where the Group has reported a loss for the period, the shares are anti-dilutive. Year ended Year ended Year ended US $ US $ US $ Loss after taxation ) ) ) Basic and diluted weighted average shares in issue Basic and diluted loss per share ) ) ) The following potentially dilutive securities outstanding at December 31, 2017, 2016 and 2015 have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive. 2017 2016 2015 Convertible promissory notes — — Warrants Share options

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2017
Intangible assets
Intangible assets	9. Intangible assets As of December 31, 2015 Cost Accumulated amortization and impairment — Net book amount at December 31, 2015 Additions — Amortization charge — Net book amount at December 31, 2016 As of December 31, 2016 Cost Accumulated amortization and impairment — Net book amount at December 31, 2016 Additions — Amortization charge — Net book amount at December 31, 2017 The Directors do not believe that the merger between Motif BioSciences Inc. and Nuprim Inc. meets the definition of an acquisition of a business as set out in IFRS 3 and is therefore accounted for as an acquisition of an asset. The fair value of the assets acquired under the merger arrangement represent the aggregate estimated value of: · 11,318,439 ordinary shares in Motif Bio plc at the placing price of 20 pence per share; · 9,432,033 warrants at the placing price of 20 pence per ordinary share; and · a milestone payment of US $500,000 to be paid by Motif BioSciences Inc. to Acino Pharma AG upon completion of the first Phase III trial. The value of the warrants has been estimated using the Black Scholes option pricing model with appropriate factors for volatility and risk-free interest rate. The Directors considered the separable value of the active pharmaceutical ingredients and determined it did not constitute a material component of the fair value of the assets acquired. No discount has been applied to the expected milestone payment of US $500,000 given management’s expectation that the liability will be settled in early 2018. Details of the purchase consideration and amounts attributed to net assets acquired are as follows: US $ Purchase consideration: Ordinary shares in Motif Bio plc Warrants to subscribe for ordinary shares in Motif Bio plc Total purchase consideration Iclaprim assets Milestone payment ) Net assets acquired As the IPR&D asset is not yet available for commercial use, no amortization has been charged to date. The Group performs an impairment test over the asset on an annual basis or when a triggering event has occurred. Based on the results of the test, no impairment was recorded in the years ended December 31, 2017 or 2016.

Prepaid expenses and other rece

Prepaid expenses and other receivables	12 Months Ended
	Dec. 31, 2017
Prepaid expenses and other receivables
Prepaid expenses and other receivables	10. Prepaid expenses and other receivables Dec 31, 2017 Dec 31, 2016 Amounts due within one year US $ US $ Prepayments and other receivables The maximum exposure to credit risk at the end of each reporting period is the fair value of each class of receivables set out above. The Group held no collateral as security. The Directors estimate that the carrying value of receivables approximated their fair value.

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Dec. 31, 2017
Cash and cash equivalents
Cash and cash equivalents	11. Cash and cash equivalents Dec 31, 2017 Dec 31, 2016 US $ US $ Cash at bank

Trade and other payables

Trade and other payables	12 Months Ended
	Dec. 31, 2017
Trade and other payables
Trade and other payables	12. Trade and other payables Dec 31, 2017 Dec 31, 2016 Amounts due within one year US $ US $ Trade payables (1) Accrued expenses — Contract research organization Accrued expenses — Other Amounts due to affiliates — Other payable (1) Trade payables include $5,704,052 owed to the Group’s contract research organization. The Directors estimate that the carrying value of trade and other payables approximated their fair value. The amounts due to the Group’s contract research organization are due in 2018.

Interest bearing loans and borr

Interest bearing loans and borrowings	12 Months Ended
	Dec. 31, 2017
Interest bearing loans and borrowings
Interest bearing loans and borrowings	13. Interest bearing loans and borrowings Dec 31, 2017 Dec 31, 2016 Non-current liabilities US $ US $ Term Loan — Deferred financing costs ) — Net non-current liabilities — On November 15, 2017, the Group entered into a credit agreement (the “Hercules Loan Agreement”) for up to $20 million in debt financing with Hercules Capital, Inc. (“Hercules”). Pursuant to the credit agreement, Hercules agreed to loan the Group $20.0 million in two tranches. The first tranche of $15.0 million was drawn down at closing, with the remaining $5.0 million available upon the achievement of certain milestones anticipated in 2018, or at Hercules’s discretion. These milestones include (i) (x) the FDA has accepted Borrower’s new drug application for marketing approval with respect to Borrower’s “Iclaprim” product for the treatment of patients with acute bacterial skin and skin structure infection (“ABSSSI”) and (y) Borrower has enrolled its first patient in its Phase 3 clinical study of Borrower’s “Iclaprim” product for the treatment of hospital-acquired bacterial pneumonia (“HABP”), (ii) Borrower has obtained market approval from the FDA with respect to Borrower’s “Iclaprim” product for the treatment of patients with ABSSSI, or (iii) at the discretion of Hercules. The terms include an initial interest-only period of 15 months, extendable to 21 months on the achievement of certain milestones; a 30-month capital and interest repayment period thereafter; an interest rate of 10% tied to the US prime rate and customary security over all assets of the Group, except for intellectual property where there is a negative pledge. In addition, there is a payment of $0.4 million due at the end of the term of the loan. Under the credit agreement, the Group issued Hercules a warrant to purchase up to 73,452 of its ADS (each representing 20 ordinary shares) at an exercise price of $9.53 per ADS, representing 3.5% warrant coverage of the total loan facility. Hercules also has the right, in its discretion, to participate in any subsequent financing, such as an equity offering, in an amount up to $1 million. In connection with the Hercules Loan Agreement closing, the Group incurred $0.5 million in fees and issued warrants with a fair value of approximately $0.4 million. Both items are classified as a direct reduction from the Hercules Loan Agreement balance and will be amortized over the life of the Loan using the effective interest rate method. The Group is also subject to an end of term charge equal to 2.15% of the total loan capacity. The end of term charge is payable upon loan maturity or the date that the Group prepays the outstanding loan balance. For the year ended December 31, 2017, the Group recognized total interest expense of $275,449, comprised of interest expense of $200,000, accretion expense related to the end of term payment of $22,758 and amortization expense related to the deferred financing costs of $52,691. Under the Hercules Loan Agreement, the Group was required to provide Hercules Capital, Inc. certain informational reports by December 30, 2017. The Group did not provide such information in a timely manner. The Group believes and represents that it has provided all required informational reports and is in compliance with covenant requirements as of December 31, 2017 and as of the date that these financial statements are issued, as we believe that the untimely provision of information did not result in an Event of Default under the terms of the loan agreement.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2017
Warrants
Warrants	14. Warrants Warrant activity The Group has issued warrants for services performed and in conjunction with various equity financings. The Group’s warrants represent ordinary shares or ADS and have either a Pounds Sterling or US Dollar exercise price. The ADS warrants are exercisable to purchase ADS’s, which each represent 20 ordinary shares. Depending on the terms of the warrant agreements, the ordinary share or ADS warrants are classified as either equity or a liability. Liability classified warrants are remeasured each reporting period, with changes in fair value recorded in the statements of comprehensive loss. The following is a summary of the Group’s warrant activity during the year ended December 31, 2017: Number of Warrants Weighted Average Ordinary shares ADS Ordinary shares ADS Outstanding as of January 1, 2017 £ $ Expired (1) ) — $ — Granted — — $ Exercised ) ) £ $ Outstanding as of December 31, 2017 £ $ (1) The ordinary warrants that expired in December 2017 had an exercise price denominated in US dollars. All other ordinary warrants have Pounds Sterling exercise prices. The Group’s warrants outstanding and exercisable as of December 31, 2017 were as follows: Type of Warrant Outstanding Number Outstanding and Exercise Price Expiration Date Ordinary shares (1) GBP £ April 2, 2020 Ordinary shares (1) GBP £ July 21, 2020 Ordinary shares (2) GBP £ November 23, 2021 ADS (2) US $ November 23, 2021 Ordinary shares (1) GBP £ April 2, 2025 ADS (2) US $ July 31, 2022 ADS (2) US $ November 14, 2022 (1) Warrants totaling 11,881,506 of ordinary shares are equity classified. (2) Warrants totaling 10,791,361 of ordinary shares and 1,336,354 of ADS are liability classified. Liability classified warrants ADS warrants On November 23, 2016, the Group closed an initial U.S. offering of 2,438,491 ADS and 1,219,246 ADS warrants at a price of US $6.98 per ADS/Warrant combination. Each ADS represents 20 ordinary shares. The warrants have an exercise price of US $8.03 per ADS and expire on November 23, 2021. In the event the Group fails to maintain the effectiveness of its Registration Statement and a Restrictive Legend Event has occurred, the warrant shall only be exercisable on a cashless basis. This would result in variability in the number of shares issued and therefore, the warrants were designated as a financial liability carried at fair value through profit and loss. On issuance of the ADS warrants, the Group recorded a derivative liability of US $3,849,160 using the Black-Scholes model. The Group develops its own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Group’s common stock, stock price volatility of comparable companies, the contractual term of the warrants, risk free interest rates and dividend yields. The Group has a limited trading history in its common stock, therefore, expected volatility is based on that of reasonably similar publicly traded companies. Due to the nature of these inputs, the valuation of the warrants is considered Level 1 and 2 measurements. On August 1, 2017, the Group issued to a third party a warrant to purchase up to 60,000 ADSs at an exercise price of $7.26 per ADS. The warrant vests 5,000 ADS at issuance, with the remaining 55,000 ADS vesting upon satisfaction of various performance conditions related to the Group’s stock price and trading volumes. Once vested, the warrant may be exercised on a cashless basis, and expires on July 31, 2022. Exercising on a cashless basis would result in variability in the number of shares issued and therefore, the warrants were designated as a financial liability carried at fair value through profit and loss. On issuance of the ADS warrants, the Group recorded a derivative liability of US $109,431 using the Black-Scholes model. At issuance, the following assumptions were used in the Black-Scholes model. August 1, 2017 Share price (US $) Exercise price (US $) Expected volatility % Number of periods to exercise Risk-free rate % Expected dividends — On November 14, 2017, in conjunction with the Hercules Loan Agreement, the Group issued Hercules a warrant to purchase up to 73,452 ADSs at an exercise price of $9.53 per ADS, representing 3.5% warrant coverage of the total loan facility. The warrant may be exercised on a cashless basis, and is immediately exercisable through November 14, 2022. Exercising on a cashless basis would result in variability in the number of shares issued and therefore, the warrants were designated as a financial liability carried at fair value through profit and loss. On issuance of the ADS warrants, the Group recorded a derivative liability of US $419,573 using the Black-Scholes model. At issuance, the following assumptions were used in the Black-Scholes model. November 14, 2017 Share price (US $) Exercise price (US $) Expected volatility % Number of periods to exercise Risk-free rate % Expected dividends — At December 31, 2017 and 2016, the liability classified ADS warrants had a fair value of US $8,927,252 and $3,967,189 using the following weighted-average assumptions in the Black-Scholes model: December 31, December 31, Share price (US $) Exercise price (US $) Expected volatility % % Number of periods to exercise Risk-free rate % % Expected dividends — — Ordinary warrants On November 23, 2016 the Group placed 22,863,428 ordinary shares together with 11,431,714 warrants over ordinary shares at a price of £0.28 per share/warrant combination. The warrants have an exercise price of £0.322 per warrant and expire on November 23, 2021. In the event that the Group fails to maintain the effectiveness of the Registration Statement, the warrant shall only be exercisable on a cashless basis. This would result in variability in the number of shares issued and therefore, the warrants were designated as a financial liability carried at fair value through profit and loss. On issuance of the warrants, the Group recorded a derivative liability of US $1,812,959 using the Black-Scholes model. At December 31, 2017 and 2016, the liability classified ordinary warrants had a fair value of US $3,699,047 and $1,830,869 using the Black-Scholes model and the following assumptions: December 31, December 31, Share price (GBP) Exercise price (GBP) Expected volatility % % Number of periods to exercise Risk free rate % % Expected dividends — — The following is a summary of the Group’s liability classified warrant activity, including both ADS and Ordinary warrants, during the years ended December 31, 2017 and 2016: Fair value Liability classified warrants $ January 1, 2016 — Issued during the year $ Loss from revaluation of derivative liabilities Balance at December 31, 2016 Issued during the year Exercised during the year ) Impact of foreign exchange Loss from revaluation of derivative liabilities Balance at December 31, 2017 $

Contingent liabilities

Contingent liabilities	12 Months Ended
	Dec. 31, 2017
Contingent liabilities
Contingent liabilities	15. Contingent liabilities On February 28, 2018, the Group’s board of directors awarded Dr. Lumsden a cash bonus of $127,500 for his performance and contributions during 2017. A portion, or $42,500, of the cash bonus is contingent upon achieving certain operational milestones in 2018. Dr. Lumsden received a separate supplemental bonus of $50,000 that is also contingent upon operational milestones in the first half of 2018. Dr. Huang was awarded a cash bonus of $142,000 for his performance and contributions in 2017. A portion, or $42,000, of the cash bonus is contingent upon achieving certain operational milestones in 2018.

Share based payments

Share based payments	12 Months Ended
	Dec. 31, 2017
Share based payments
Share based payments	16. Share based payments Motif BioSciences Inc. issued options and warrants to employees, directors, consultants, and note holders. As part of the merger between Motif Acquisition Sub, Inc. and Motif BioSciences Inc., described in Note 1, each outstanding share option granted by Motif BioSciences Inc. was assumed and converted by Motif Bio plc into options to subscribe for ordinary shares in Motif Bio plc. The number of share options and the exercise prices have been adjusted to reflect the reverse stock split in the capital of Motif BioSciences Inc. on March 13, 2015. On December 4, 2014, Motif BioSciences Inc. adopted a Share Option Plan (the “Plan”) under which options can be granted to employees, consultants, and directors. The share price used for the Plan prior to being traded on AIM was based on management’s assessment of the valuation of the Group given the net assets and future potential of the Group at the time of granting. Motif Bio plc adopted a Share Option Plan (the “New Plan”) on April 1, 2015. The New Plan replaces Motif BioSciences Inc.’s previous share plan. There were no changes to the fair value of share options granted under the Plan with the only change being to grant the holders shares in Motif Bio plc rather than Motif BioSciences Inc. upon exercising options. The exercise price for each option will be established at the discretion of the Board provided that the exercise price for each option shall not be less than the nominal value of the relevant shares if the options are to be satisfied by a new issue of shares by the Company and provided that the exercise price per share for an option shall not be less than the fair market value of a share on the effective date of grant of the option. Options will be exercisable at such times or upon such events and subject to such terms, conditions and restrictions as determined by the Board on grant date. However, no option shall be exercisable after the expiration of ten years after the effective date of grant of the option. Weighted average Number of exercise price share options US $ Outstanding at January 1, 2016 Granted during the year Forfeited during the year — — Exercised during the year ) Expired during the year ) Outstanding at December 31, 2016 Granted during the year Forfeited during the year ) Exercised during the year ) Expired during the year — — Outstanding at December 31, 2017 Exercisable at December 31, 2017 The range of exercise prices of the options at December 31, 2017 was US $0.14 - $0.91. The weighted average contractual term of options outstanding at December 31, 2017 and 2016 was 7.0 years and 7.3 years, respectively. The weighted average remaining contractual term of options exercisable at December 31, 2017 was 6.1 years. The fair value of options granted have been valued using the Black Scholes option pricing model. The weighted-average fair value of options granted during the year ended December 31, 2017 was $0.26. Volatility is based on reported data from selected reasonably similar publicly traded companies for which the historical information is available. The Group does not have sufficient history to estimate the volatility of its share price. The weighted-average assumptions for option grants were as follows: Year ended Dec Share price (US $) 0.34 Exercise price (US $) 0.34 Expected volatility 70.86% Term 10 years Risk free rate 2.11% Expected dividends — The total expense recognized for the years arising from stock-based payments are as follows: Year ended Dec Year ended Dec Year ended Dec US $ US $ US $ General and administrative expense Research and development expense — — Total share-based payment expense During the preparation of the interim financial statements for the six months ended June 30, 2017, the Group identified and corrected a prior period error whereby stock based compensation expense was understated primarily due to recognizing expense only when an award vested, not over the required service period using a graded vesting approach as required under IFRS 2. The Group assessed the materiality of the out-of-period adjustments on all impacted periods and determined that they were not material to any of the periods and that a restatement of previously issued financial statements was not required. The Group concluded that the cumulative adjustment to correct the error should be recorded in the year ended December 31, 2017. The expense in fiscal years 2016 and 2015 and 2014 was understated by $802,282, $291,696 and $31,799, respectively. The out-of-period correction increased General and Administrative expense by $762,836 and Research and Development expense by $362,941 for the year ended December 31, 2017. None of these adjustments had an impact on the cash resources of the Group.

Share capital

Share capital	12 Months Ended
	Dec. 31, 2017
Share capital
Share capital	17. Share capital Allotted, called up and fully paid: Number US $ In issue at December 31, 2015 Issued: Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each In issue at December 31, 2016 Issued: Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each In issue at December 31, 2017 On September 9, 2016, Motif Bio plc issued 409,000 ordinary shares to Amphion Innovations plc as part of the terms of the renegotiated convertible promissory notes. On November 23, 2016, Motif Bio plc issued 2,438,491 ADSs upon the closing of an initial U.S. offering and 1,219,246 warrants over ADS at a price of US $6.98 per ADS/Warrant combination. Each ADS represents 20 ordinary shares. On November 23, 2016, Motif Bio plc issued 22,863,428 ordinary shares together with 11,431,714 warrants over ordinary shares at a price of 28 pence per share/warrant combination. On November 29, 2016, 119,990 ordinary shares were issued upon the exercise of options. In December 2016, 467,024 ordinary shares were issued upon the exercise of options and warrants. In December 2016, Motif Bio plc issued 14,510,770 new ordinary shares following the conversion of convertible promissory notes by Amphion Innovations plc and Amphion Innovations US Inc. The notes which totaled US $3,550,786 were converted in accordance with their terms at US $0.2447 per share. In January 2017, 143,700 ordinary shares were issued upon the exercise of options. In May 2017, 326,880 ordinary shares were issued upon the exercise of warrants. In June 2017, Motif Bio plc issued 66,666,667 ordinary shares at a price of 30 pence per share. In July 2017, 250,000 ordinary shares were issued upon the exercise of warrants. In November 2017, a total of 390,353 ordinary shares were issued upon the exercise of warrants. Share premium represents the excess over nominal value of the fair value consideration received for equity shares net of expenses of the share issue. Retained deficit represents accumulated losses. The group re-organization reserve arose when Motif Bio plc became the parent of the Group. The transaction, falling as it does outside the scope of IFRS 3, has been accounted for as a group re-organization and not a business combination. The re-organization reserve can be derived by calculating the difference between the nominal value of the shares in Motif Bio plc issued to the former shareholders in Motif BioSciences Inc. and the share capital and share premium of Motif BioSciences Inc. at the date of the merger.

Financial assets and financial

Financial assets and financial liabilities	12 Months Ended
	Dec. 31, 2017
Financial assets and financial liabilities
Financial assets and financial liabilities	18. Financial assets and financial liabilities The Group holds the following financial instruments: Financial assets at amortized cost Financial assets US $ 2017 Prepaid expenses and other receivables Cash and cash equivalents 2016 Prepaid expenses and other receivables Cash and cash equivalents Financial liabilities at amortized cost Financial liabilities US $ 2017 Trade and other payables Payable on completion of clinical trial Derivative liabilities 2016 Trade and other payables Payable on completion of clinical trial Derivative liabilities Fair value disclosures The Group’s cash, prepaid expenses and other current assets and trade and other payables are stated at their respective historical carrying amounts, which approximates fair value due to their short-term nature. These are measured at fair value using Level 1 inputs. The Group’s derivative liabilities are measured at fair value using Level 1 or 2 inputs. See discussion in Note 14 on the inputs utilized in the Black-Scholes option pricing model and for a rollforward of the derivative liability from December 31, 2016 to December 31, 2017. The Group determined that the book value of the Hercules Loan Agreement (Note 13) approximates its fair value as of December 31, 2017 due the proximity of the transaction date with December 31, 2017 and the interest being tied to the U.S. Prime Rate. There were no transfers between fair value levels during the years ended December 31, 2017 or 2016. There were no non-recurring fair value measurements for the years ended December 31, 2017 or 2016. When measuring the fair value of an asset or a liability, the Group uses observable market data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: · Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities. · Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices). · Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Subsidiaries

Subsidiaries	12 Months Ended
	Dec. 31, 2017
Subsidiaries
Subsidiaries	19. Subsidiaries Method used Country of Percentage Percentage to account for Company name incorporation shareholding voting power investment Motif BioSciences Inc. Delaware, USA % % Consolidation The principal activity of Motif BioSciences Inc. is proprietary drug discovery research and development.

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2017
Related party transactions
Related party transactions	20. Related party transactions Transactions with Amphion Innovations plc and Amphion Innovations US, Inc. At December 31, 2017, Amphion Innovations plc and its wholly owned subsidiary, Amphion Innovations US, Inc., or collectively, the Amphion Group owned 14.48% of the issued ordinary shares in Motif Bio plc. In addition, the Amphion Group previously provided funding for the activities of Motif BioSciences Inc. through the issue of convertible interest bearing loan notes, which were converted to shares in December 2016. Richard Morgan and Robert Bertoldi were directors of both the Company and Amphion Innovations plc in the period. Transactions between the Group and the Amphion Group are disclosed below: Advisory And Consultancy Agreement With Amphion Innovations US, Inc. On April 1, 2015, the Group entered into an Advisory and Consultancy Agreement with Amphion Innovations US, Inc. The consideration for the services is $120,000 per annum. The agreement was amended in December 2016 so that either party may terminate the agreement at any time, for any reason, upon giving the other party ninety-days advance written notice. The Group paid $120,000 to Amphion Innovations US, Inc. during each year ending December 31, 2017 and 2016 in accordance with the terms of the agreement. As of the date of this annual report, the agreement continues to be in force. Consultancy Agreement With Amphion Innovations plc On April 1, 2015, the Group entered into a Consultancy Agreement with Amphion Innovations plc for the services of Robert Bertoldi, an employee of Amphion Innovations plc. The consideration for his services was $5,000 per month. On November 1, 2015, the consideration was increased to $180,000 per annum. On July 1, 2016, the consideration decreased to US $75,000 per annum. The agreement was for an initial period of 12 months and would automatically renew each year on the anniversary date unless either party notifies the other by giving ninety-days written notice prior to expiration. The agreement was amended in December 2016 so that either party may terminate the agreement at any time, for any reason, upon giving the other party ninety-days advance written notice. In July 2017, the Group amended the consulting agreement with Amphion Innovations plc to increase the annual consideration to $125,000 to better reflect Robert Bertoldi’s time commitment to the Group with and effective date of January 1, 2017. The Group paid Robert Bertoldi $125,000 and $127,500 during the years ended December 31, 2017 and 2016 in accordance with the terms of the agreement. Consultancy Agreement With Amphion Innovations US, Inc. On September 7, 2016, the Group entered into a Consultancy Agreement with Amphion Innovations US, Inc., pursuant to which Amphion Innovations US, Inc. will provide consultancy services in relation to the Group’s obligations as a NASDAQ listed company. The consideration for the services was $15,500 per month. The agreement was for an initial period of 12 months, after which the agreement will terminate automatically unless renewed by the parties by mutual agreement. The agreement was not extended past the initial term. The Group paid $170,500 and $19,633 during the years ended December 31, 2017 and 2016 in accordance with the terms of the agreement. Consultancy Agreement With Jonathan Gold On April 13, 2016, the Group entered into a consultancy agreement with Mr. Gold, a member of the Group’s Board of Director. Under the terms of this agreement, Mr. Gold received a fixed fee of $10,000 per month for strategic financial expert advice and guidance. The term of this agreement was six months, commencing January 1, 2016. The term of the agreement would automatically renew each month following the initial term, provided that each party provided its mutual agreement to renew in a signed writing, no later than 30 days prior to the expiration of the term. This agreement was not extended beyond the initial term. On April 7, 2017, the Group entered into a new consultancy agreement with Mr. Gold. Under the terms of this agreement, Mr. Gold received a fixed fee of $16,167 per month for strategic financial expert advice and guidance. The term of this agreement was twelve months, commencing January 1, 2017. The term of the agreement would automatically renew each month following the initial term, as long as either party did not provide notice to the other party of its election not to continue to renew the agreement with at least 30-days advance notice. In connection with Mr. Gold assuming the executive role as Chief Financial Officer of February 2, 2018, this agreement was suspended as of December 31, 2017.

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2017
Subsequent events
Subsequent events	21. Subsequent events On January 19, 2018, the Group announced that it had filed a “universal” shelf registration statement on Form F-3 with the SEC, which was declared effective by the SEC on January 31, 2018. The filing of a shelf registration statement, a common practice by NASDAQ-listed companies, is intended to provide the Group with more timely and efficient access to the U.S. capital markets. The shelf registration, which can remain effective for up to three years, will enable the Company to offer, issue and sell, in one or more offerings at any time (as long as the shelf registration statement remains effective), up to an aggregate of $80 million of ordinary shares, including ADSs, where each ADS represents 20 ordinary shares), preference shares, warrants, subscription rights, debt securities and a combination of such securities, separately or as units. The Group currently has no specific plans to issue securities under this shelf registration. The specifics of any future offering, including the prices and terms of any securities offered by the Group, would be determined at the time of any such offering and would be described in detail in a prospectus supplement filed in connection with such offering. Effective February 2, 2018, Jonathan Gold assumed the executive role of Chief Financial Officer upon the resignation of Robert Dickey IV, the Group’s former Chief Financial Officer. On April 3, 2018, the Group announced the initiation of a rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for iclaprim. The Group commenced the submission before the end of the first quarter of 2018 and is expecting to complete the submission of the full NDA during the second quarter of 2018. The Group also announced that it received correspondence from the FDA that a small business waiver has been granted for the NDA application fee which is typically due upon submission of an NDA under the Prescription Drug User Fee Act (PDUFA). As a result, the Group did not have to pay a $2.4 million application fee for this NDA submission.

Significant accounting polici27

Significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2017
Significant accounting policies
Basis of preparation	a. Basis of preparation The accounting policies set out below have been applied consistently to all periods presented in this financial information. The financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and in conformity with IFRS as adopted by the European Union. This basis of preparation describes how the financial statements have been prepared in accordance with IFRS. The financial statements have been prepared under the historical cost convention. A summary of the more important Group accounting policies is set out below. The preparation of financial statements in conformity with IFRS requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial information and the reported amounts of revenue and expenses during the period. Although these estimates are based on management’s best knowledge of the amount, event or actions, actual results ultimately may differ from those estimates. a. New and amended standards effective from January 1, 2017 Amendments to IAS 7, Disclosure Initiative, was adopted with an effective date of January 1, 2017. The amendments require disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities, including both changes arising from cash flow and non-cash changes. The Group believes that the disclosure contained herein adequately satisfy this requirement. The only balance sheet liability for which cash flows are classified as financing activities is the term loan with Hercules Capital, Inc. The cash inflow in the year in respect of the term loan was $14.4 million, net of issuance costs and non-cash movement of $0.4 million for the issuance of warrants. The net movement and resulting closing balance is further detailed in Note 13. There are no other new standards and amendments that have been applied from January 1, 2017, which have had an impact on the Group’s financial statements. New standards and interpretations not yet effective Certain new accounting standards and interpretations have been published that are not mandatory for the reporting periods covered by these consolidated financial statements and have not been early adopted by the Group. The new standards potentially relevant to the Group are discussed below. IFRS 2, Share-based Payments (as amended) — Effective date — January 1, 2018. The Group currently plans to apply IRFS 2 initially on January 1, 2018. IFRS 2 related to the classification and measurement of share-based payment transactions. The amendments are intended to eliminate diversity in practice regarding (i) accounting for cash-settled share-based payment transactions that include a performance condition, (ii) share-based payments in which the manner of settlement is contingent on future events, (iii) share-based payments settled net of tax withholdings, and (iv) modification of share-based payment transactions from cash-settled to equity-settled. Based on the initial assessment, this standard is not expected to have a material impact on the Group. IFRS 9, Financial Instruments (as revised in 2014) — Effective date — January 1, 2018, with early adoption permitted. The Group currently plans to apply IRFS 9 initially on January 1, 2018. IFRS 9 includes revised guidance on the classification and measurement of financial instruments, a new expected credit loss model for calculating impairment on financial assets, and new general hedge accounting requirements. Based on the initial assessment, this standard is not expected to have a material impact on the Group. IFRS 15, Revenue from Contracts with Customers — Effective date — January 1, 2018, with early adoption permitted. — IFRS 15 establishes a comprehensive guideline for determining when to recognize revenue and how much revenue to recognize. The Group currently has no revenues, therefore, the adoption of IFRS 15 is not expected to have a material impact on the Group, however, the Group will continue to reassess the potential impact of the adoption of this guidance. IFRS 16, Leases — Effective date — January 1, 2019 — IFRS 16 will replace IAS 17. It will eliminate the distinction between classification of leases as finance or operating leases for lessees. The adoption of IFRS 16 is not expected to have a significant impact on the Group’s net results or net assets, however, the Group will continue to reassess the potential impact of the adoption of this guidance as the effective date becomes closer. Principles of consolidation Subsidiaries are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases. Intercompany transactions, balances, and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. When the Group ceases to consolidate because of a loss of control, any retained interest in the entity is remeasured to its fair value with the change in carrying amount recognized in profit or loss. This fair value becomes the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate, joint venture, or financial asset.
Segment reporting	b. Segment reporting The chief operating decision-maker is considered to be the Board of Directors of Motif Bio plc. The chief operating decision-maker allocates resources and assesses performance of the business and other activities at the operating segment level. In addition, they review the IFRS consolidated financial statements. The chief operating decision-maker has determined that Motif has one operating segment to support its strategy for the development and commercialization of pharmaceutical formulations. The Group maintains space and has some activities in the U.K.; however, the finance and most other management functions take place in the U.S.
Foreign currency translation	c. Foreign currency translation (a) Functional and Presentation Currency Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The consolidated financial statements are presented in United States Dollars (US $), which is Motif Bio plc’s functional and presentation currency. (b) Transactions and balances Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss. They are deferred in equity if they relate to qualifying cash flow hedges and qualifying net investment hedges or are attributable to part of the net investment in a foreign operation. Foreign exchange gains and losses that relate to borrowings are presented in the statement of profit or loss, within finance costs. All other foreign exchange gains and losses are presented in the statement of profit or loss on a net basis within other income or other expenses. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as available-for-sale financial assets are recognized in other comprehensive income.
Research and development costs	d. Research and development costs Expenditure on drug development activities is capitalized only if all of the following conditions are met: · it is probable that the asset will create future economic benefits; · the development costs can be measured reliably; · technical feasibility of completing the intangible asset can be demonstrated; · there is the intention to complete the asset and use or sell it; · there is the ability to use or sell the asset; and · adequate technical, financial, and other resources to complete the development and to use or sell the asset are available. These conditions are generally met when a filing is made for regulatory approval for commercial production. Otherwise, costs on research activities are recognized as an expense in the period in which they are incurred. At this time, the Group does not meet all conditions and therefore development costs are recorded as expense in the period in which the cost is incurred. The Group’s preclinical studies and clinical trials have been performed utilizing third-party contract research organizations (“CROs”) and other vendors. For preclinical studies, the significant factors used in estimating accruals include the percentage of work completed to date and contract milestones achieved. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, duration of enrollment, percentage of work completed to date and contract milestones achieved. The Group monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence and status meetings and review of contractual terms. Estimates are dependent on the timeliness and accuracy of data provided by the CROs and other vendors. In this event, the Group could record adjustments to research and development expenses in future periods when the actual activity levels become known.
Intangible assets	e. Intangible assets Intangible assets acquired separately from a business are initially stated at cost, net of any amortization and any provision for impairment. Where a finite useful life of the acquired intangible asset cannot be determined, the asset is not subject to amortization but is tested for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
Impairment of non-financial assets	f. Impairment of non-financial assets Assets that have an indefinite useful life are not subject to amortization and are tested annually in the second half of each fiscal year for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.
Financial instruments-initial recognition and subsequent measurement	g. Financial instruments—initial recognition and subsequent measurement A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. a) Financial assets, initial recognition and measurement All financial assets, such as receivables and deposits, are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. The Group assesses, at each reporting date, whether there is objective evidence that a financial asset or a group of financial assets is impaired. An impairment exists if one or more events that has occurred since the initial recognition of the asset (an incurred “loss event”), has an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated. b) Financial liabilities, initial recognition and measurement Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, and payables, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Company’s financial liabilities include trade and other payables, loans and borrowings and warrants classified as liabilities. c) Subsequent measurement The measurement of financial liabilities depends on their classification. Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial assets at fair value through profit or loss are subsequently carried at fair value. Loans and receivables are subsequently carried at amortized cost using the effective interest method if the time value of money is significant.
Financial assets and liabilities	h. Financial assets and liabilities Financial assets and financial liabilities are included in the Group’s balance sheet when the Group becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the investments have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Non-derivative financial instruments Cash and cash equivalents Cash and cash equivalents include bank balances, demand deposits, and other short-term, highly liquid investments (with less than three months to maturity) that are readily convertible into a known amount of cash and are subject to an insignificant risk of fluctuations in value. Financial liabilities and equity The Group classifies an instrument, or its component parts, on initial recognition as a financial liability or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability and an equity instrument. An instrument is classified as a financial liability when it is either (i) a contractual obligation to deliver cash or another financial asset to another entity; or (ii) a contract that will or may be settled in the Group’s own equity instruments and is a non-derivative for which the Group is, or may be, obliged to deliver a variable number of the Group’s own equity instruments or a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Group’s own equity instruments. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds. An equity instrument is defined as any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. An instrument is an equity instrument only if the issuer has an unconditional right to avoid settlement in cash or another financial asset. Trade payables Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities. Trade payables are initially measured at fair value, and are subsequently measured at amortized cost, using the effective interest rate method. Equity instruments Equity instruments issued by the Company are recorded at the proceeds received. Direct issuance costs are processed as a deduction on equity. Derivative financial instruments The Group does not have a policy of engaging in speculative transactions, nor does it issue or hold financial instruments for trading purposes. The Group has entered into various financing arrangements with its investors, including convertible loans. These convertible loans each include embedded financial derivative elements (being the right to acquire equity in the Group at a future date for a pre-determined price). Therefore, while the Group does not engage in speculative trading of derivative financial instruments, it may hold such instruments from time to time as part of its financing arrangements. The Group has also entered into financing arrangements that include the issuance of warrants. These warrants may be considered derivative financial instruments based on the terms of the agreements. Derivatives are initially recognized at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. The resulting gain or loss is recognized in the consolidated income statement, as the Group currently does not apply hedge accounting. Impairment of financial assets The Group assesses at the end of each reporting period whether there is objective evidence that a financial asset or group of financial assets is impaired. A financial asset or a group of financial assets is impaired and impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a “loss event”) and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated. Evidence of impairment may include indications that the debtors or a group of debtors is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization, and where observable data indicate that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or economic conditions that correlate with defaults. For loans and receivables category, the amount of the loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset’s original effective interest rate. The carrying amount of the asset is reduced and the amount of the loss is recognized in the consolidated income statement. If a loan or held-to-maturity investment has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. As a practical expedient, the Group may measure impairment on the basis of an instrument’s fair value using an observable market price. If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized (such as an improvement in the debtor’s credit rating), the reversal of the previously recognized impairment loss is recognized in the consolidated income statement.
Offsetting financial instruments	i. Offsetting financial instruments Financial assets and liabilities are offset and the net amount is reported in the balance sheet when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency, or bankruptcy of the Company or the counterparty.
Share-based payment transactions	j. Share-based payment transactions The fair value of options and warrants granted to employees, directors, and consultants is recognized as an expense, with a corresponding increase in equity, over the period in which the option and warrant holders become unconditionally entitled to the options and warrants unless incremental and directly attributable to an equity transaction in which case it is deducted from equity. The fair value of the options and warrants granted is measured using an option valuation model, taking into account the terms and conditions upon which the options were granted.
Financial income and expenses	k . Financial income and expenses Financial income comprises interest receivable on funds invested. Financial expenses comprise interest payable. Interest income and interest payable are recognized in the income statement as they accrue, using the effective interest method.
Taxation	l . Taxation Tax on the profit or loss for the year comprises current and deferred tax. Tax is recognized in the income statement except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantively enacted at the balance sheet date and any adjustment to tax payable in respect of previous years. Deferred tax is provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: the initial recognition of goodwill; the initial recognition of assets or liabilities that affect neither accounting nor taxable profit other than in a business combination; and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized.
Earnings per share	m. Earnings per share The Company presents basic and diluted earnings per share (EPS) data for its shares. Basic EPS is calculated by dividing the profit or loss attributable to shares of the Company by the weighted average number of shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to shareholders and the weighted average number of shares outstanding for the effects of all dilutive potential shares, which comprise share options and warrants granted to employees and non-employees. In periods when the Company has a loss attributable to shareholders, diluted EPS equates to basic EPS.
Borrowings	n. Borrowings Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method.
Equity	o. Equity The Company classifies an instrument, or its component parts, on initial recognition as a financial liability or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability and an equity instrument. An instrument is classified as a financial liability when it is either (i) a contractual obligation to deliver cash or another financial asset to another entity; or (ii) a contract that will, or may be, settled in the Company’s own equity instruments and is a non-derivative for which the Company is, or may be, obliged to deliver a variable number of the Company’s own equity instruments or a derivative that will or may be settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company’s own equity instruments. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds. An equity instrument is defined as any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. An instrument is an equity instrument only if the issuer has an unconditional right to avoid settlement in cash or another financial asset. Ordinary Shares Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction from the proceeds
Critical accounting estimates and judgments	p. Critical accounting estimates and judgments In preparing the financial information, the Directors make judgments on how to apply the Group’s accounting policies and make estimates about the future. The critical judgments that have been made in arriving at the amounts recognized in the financial information and the key sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying value of assets and liabilities in the next financial year, are discussed below: Acquisition and valuation of the iclaprim assets The directors, on assessing if the acquisition of the Nuprim iclaprim assets was of a business or of a group of assets, considered: · the identified elements of the acquired group; · the capability of the acquired group to produce outputs; and · the impact that any missing elements have on a market participant’s ability to produce outputs with the acquired group. As the acquired group was not accompanied by any associated processes and because the acquired assets do not have planned principal activities, or a plan to produce outputs, the Directors considered the acquisition to be of a group of assets, not a business. The Directors use their judgment to identify the separate intangible assets and then determine a fair value for each based upon the consideration paid, the nature of the asset, industry statistics, future potential, and other relevant factors. Asset acquisitions are measured based on their cost to the acquiring entity, which generally includes transaction costs. An asset’s acquisition cost or the consideration transferred by the acquiring entity is assumed to be equal to the fair value of the net assets acquired, unless contrary evidence exists. These fair values are tested for impairment annually. Research and development expenditures Research and development expenditures are currently not capitalized because the criteria for capitalization are not met. At each balance sheet date, the Group estimates the level of service performed by the vendors and the associated costs incurred for the services performed. Although the Group does not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period. Share based payments and fair value of warrants The Directors have to make judgments when deciding on the variables to apply in arriving at an appropriate valuation of share based compensation and warrants, including appropriate factors for volatility, risk free interest rate, and applicable future performance conditions and exercise patterns.

Financial risk management (Tabl

Financial risk management (Tables)	12 Months Ended
	Dec. 31, 2017
Financial risk management
Schedule of contractual maturities of financial liabilities	Between 1 Between 2 < 1 year and 2 years and 5 years Over 5 years At December 31, 2017 US $ US $ US $ US $ Total Trade and other payables — — — Payable on completion of clinical trial — — — Derivative liabilities — — — Term Loan and other non-current (Note 13) — — — Between 1 Between 2 < 1 year and 2 years and 5 years Over 5 years At December 31, 2016 US $ US $ US $ US $ Total Trade and other payables — — — Payable on completion of clinical trial — — — Derivative liabilities — — — — —
Schedule of carrying amounts of foreign currency denominated monetary net assets	December 31, 2017 December 31, 2016 US $ US $ Sterling - Cash

Other income and expense items

Other income and expense items (Tables)	12 Months Ended
	Dec. 31, 2017
Other income and expense items
Schedule of other income	Year ended Dec Year ended Dec Year ended Dec US $ US $ US $ Gains on settlement of contract disputes —
Schedule of breakdown of expenses by nature	Year ended Dec Year ended Dec Year ended Dec US $ US $ US $ General and administrative expenses Employee benefits expenses, including share-based payments Directors’ fees Legal and professional fees Investor and public relations advisory fees Other expenses Research and development costs Employee benefits expenses, including share-based payments — Contract research organization expenses Chemistry and manufacturing development and other non-clinical development Other research and development costs 2017 2016 2015 Auditors’ Remuneration US $ US $ US $ Audit Fees Audit-Related Fees — — — Tax Fees — — — Other Fees — — — Total
Schedule of finance income and costs	Year ended Dec Year ended Dec Year ended Dec US $ US $ US $ Finance income Interest from financial assets Finance costs Interest expense ) ) ) Accretion of end of term payment ) — — Amortization of deferred financing costs ) — — ) ) ) Net finance costs ) ) )

Employee numbers and costs (Tab

Employee numbers and costs (Tables)	12 Months Ended
	Dec. 31, 2017
Employee numbers and costs
Schedule of monthly average number of persons employed by the Group	Year ended Year ended Year ended Executive Directors Key management personnel Total
Schedule of aggregate payroll costs of Executive Directors and key management personnel	Year ended Year ended Year ended US $ US $ US $ Short term benefits: Wages and salaries Social security and other employer costs Share based payments(1) (1) The total share based payments does not reflect the out-of-period adjustment recorded in 2017 (Note 16).

Directors' remuneration (Tables

Directors' remuneration (Tables)	12 Months Ended
	Dec. 31, 2017
Directors' remuneration
Schedule of directors remuneration	Salaries Social 2017 2016 2015 and fees Bonuses Security Total Total Total US $ US $ US $ US $ (2) US $ US $ Executive Graham Lumsden(1)(2) Non-executive Robert Bertoldi(2) — Richard Morgan — — Charlotta Ginman(3) — — Jonathan Gold — — Zaki Hosny — — Mary Lake Polan — — John Stakes(4) — — — — Bruce Williams — — Craig T. Albanese — — — — Total (1) On February 28, 2018, Dr. Lumsden was awarded a cash bonus of $127,500 for services provided in 2017. A portion, or $42,500, of the cash bonus is contingent on meeting certain operational milestones in 2018. (2) Total remuneration for Dr. Lumsden and Mr. Bertoldi exclude employer 401k pension contributions of $7,950 and $6,075, respectively, during 2017. (3) Ms. Ginman’s remuneration for 2017 was £52,195 or US $67,279 based on an average exchange rate of 1.289 for the period. (4) Mr. Stakes resigned from the Board of Directors effective July 1, 2016.
Schedule of directors of the company have been awarded rights to subscribe for shares in the Group	Exercise January 1, December 31, price Grant Expiry 2017 Granted 2017 US $ date date Richard Morgan — $ Jan 1, 2010 Jan 1, 2020 — $ Jan 1, 2011 Jan 1, 2021 — Dec 4, 2014 Dec 4, 2024 — Craig T. Albanese — $ May 4, 2017 May 4, 2027 — Robert Bertoldi — $ Jan 1, 2010 Jan 1, 2020 — $ Dec 4, 2014 Dec 4, 2024 — Charlotta Ginman — $ Dec 4, 2014 Dec 4, 2024 — Jonathan Gold — $ Jan 1, 2010 Jan 1, 2020 — $ Jan 1, 2011 Jan 1, 2021 — $ Dec 4, 2014 Dec 4, 2024 — Zaki Hosny — $ Jun 18, 2009 Jun 18, 2019 — $ Jan 1, 2010 Jan 1, 2020 — $ Jan 1, 2011 Jan 1, 2021 — $ Jan 30, 2013 Jan 30, 2023 — $ Dec 4, 2014 Dec 4, 2024 — Graham Lumsden — $ May 25, 2013 May 25, 2023 — $ Dec 4, 2014 Dec 4, 2024 — $ Feb 7, 2017 Feb 7, 2027 — $ Feb 7, 2017 Feb 7, 2027 Mary Lake Polan — $ Jan 1, 2010 Jan 1, 2020 — $ Jan 1, 2011 Jan 1, 2021 — $ Dec 4, 2014 Dec 4, 2024 — Bruce Williams — $ Jan 1, 2010 Jan 1, 2020 — $ Jan 16, 2010 Jan 16, 2020 — $ Nov 15, 2010 Jan 16, 2020 — $ Jan 1, 2011 Jan 1, 2021 — $ Dec 4, 2014 Dec 4, 2024 —

Income tax expense (Tables)

Income tax expense (Tables)	12 Months Ended
	Dec. 31, 2017
Income tax expense
Schedule of current tax expense	Year Year ended Year ended Current tax expense US $ US $ US $ U.K. corporation taxes — — — Overseas taxes
Schedule of reconciliation of effective tax rate	2017 2016 2015 Reconciliation of effective tax rate: US $ US $ US $ Loss on ordinary activities before taxation ) ) ) U.K. Corporation tax at 19% ) ) ) Overseas tax at higher rate ) ) ) Effects of: Unrecognized losses ) ) ) Other adjustments-overseas taxes Total tax charge

Loss per share (Tables)

Loss per share (Tables)	12 Months Ended
	Dec. 31, 2017
Loss per share
Schedule of basic and diluted loss per share	Year ended Year ended Year ended US $ US $ US $ Loss after taxation ) ) ) Basic and diluted weighted average shares in issue Basic and diluted loss per share ) ) )
Schedule of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding , as they would be antidilutive	2017 2016 2015 Convertible promissory notes — — Warrants Share options

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2017
Intangible assets
Schedule of intangible assets	As of December 31, 2015 Cost Accumulated amortization and impairment — Net book amount at December 31, 2015 Additions — Amortization charge — Net book amount at December 31, 2016 As of December 31, 2016 Cost Accumulated amortization and impairment — Net book amount at December 31, 2016 Additions — Amortization charge — Net book amount at December 31, 2017
Schedule of purchase consideration amounts attributed to net assets acquired	US $ Purchase consideration: Ordinary shares in Motif Bio plc Warrants to subscribe for ordinary shares in Motif Bio plc Total purchase consideration Iclaprim assets Milestone payment ) Net assets acquired

Prepaid expenses and other re35

Prepaid expenses and other receivables (Tables)	12 Months Ended
	Dec. 31, 2017
Prepaid expenses and other receivables
Schedule of prepaid expenses and other receivables	Dec 31, 2017 Dec 31, 2016 Amounts due within one year US $ US $ Prepayments and other receivables

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	12 Months Ended
	Dec. 31, 2017
Cash and cash equivalents
Schedule of cash and cash equivalents	Dec 31, 2017 Dec 31, 2016 US $ US $ Cash at bank

Trade and other payables (Table

Trade and other payables (Tables)	12 Months Ended
	Dec. 31, 2017
Trade and other payables
Schedule of trade and other payables	Dec 31, 2017 Dec 31, 2016 Amounts due within one year US $ US $ Trade payables (1) Accrued expenses — Contract research organization Accrued expenses — Other Amounts due to affiliates — Other payable (1) Trade payables include $5,704,052 owed to the Group’s contract research organization.

Interest bearing loans and bo38

Interest bearing loans and borrowings (Tables)	12 Months Ended
	Dec. 31, 2017
Interest bearing loans and borrowings
Schedule of interest bearing loans and borrowings	Dec 31, 2017 Dec 31, 2016 Non-current liabilities US $ US $ Term Loan — Deferred financing costs ) — Net non-current liabilities —

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Warrants
Schedule of warrant activity	Number of Warrants Weighted Average Ordinary shares ADS Ordinary shares ADS Outstanding as of January 1, 2017 £ $ Expired (1) ) — $ — Granted — — $ Exercised ) ) £ $ Outstanding as of December 31, 2017 £ $ (1) The ordinary warrants that expired in December 2017 had an exercise price denominated in US dollars. All other ordinary warrants have Pounds Sterling exercise prices.
Schedule of warrants outstanding and exercisable	The Group’s warrants outstanding and exercisable as of December 31, 2017 were as follows: Type of Warrant Outstanding Number Outstanding and Exercise Price Expiration Date Ordinary shares (1) GBP £ April 2, 2020 Ordinary shares (1) GBP £ July 21, 2020 Ordinary shares (2) GBP £ November 23, 2021 ADS (2) US $ November 23, 2021 Ordinary shares (1) GBP £ April 2, 2025 ADS (2) US $ July 31, 2022 ADS (2) US $ November 14, 2022 (1) Warrants totaling 11,881,506 of ordinary shares are equity classified. (2) Warrants totaling 10,791,361 of ordinary shares and 1,336,354 of ADS are liability classified.
Schedule of assumptions used in fair value of derivative liability of warrants over ADS	August 1, 2017 Share price (US $) Exercise price (US $) Expected volatility % Number of periods to exercise Risk-free rate % Expected dividends — November 14, 2017 Share price (US $) Exercise price (US $) Expected volatility % Number of periods to exercise Risk-free rate % Expected dividends — December 31, December 31, Share price (US $) Exercise price (US $) Expected volatility % % Number of periods to exercise Risk-free rate % % Expected dividends — —
Schedule of assumptions used in fair value of derivative liability of warrants over Ordinary shares	December 31, December 31, Share price (GBP) Exercise price (GBP) Expected volatility % % Number of periods to exercise Risk free rate % % Expected dividends — —
Schedule of warrant liability	Fair value Liability classified warrants $ January 1, 2016 — Issued during the year $ Loss from revaluation of derivative liabilities Balance at December 31, 2016 Issued during the year Exercised during the year ) Impact of foreign exchange Loss from revaluation of derivative liabilities Balance at December 31, 2017 $

Share based payments (Tables)

Share based payments (Tables)	12 Months Ended
	Dec. 31, 2017
Share based payments
Schedule of number of share options and weighted average exercise price	Weighted average Number of exercise price share options US $ Outstanding at January 1, 2016 Granted during the year Forfeited during the year — — Exercised during the year ) Expired during the year ) Outstanding at December 31, 2016 Granted during the year Forfeited during the year ) Exercised during the year ) Expired during the year — — Outstanding at December 31, 2017 Exercisable at December 31, 2017
Schedule of weighted-average assumptions for option grants	Year ended Dec Share price (US $) 0.34 Exercise price (US $) 0.34 Expected volatility 70.86% Term 10 years Risk free rate 2.11% Expected dividends —
Schedule of expense recognized from stock-based payments	Year ended Dec Year ended Dec Year ended Dec US $ US $ US $ General and administrative expense Research and development expense — — Total share-based payment expense

Share capital (Tables)

Share capital (Tables)	12 Months Ended
	Dec. 31, 2017
Share capital
Schedule of share capital	Allotted, called up and fully paid: Number US $ In issue at December 31, 2015 Issued: Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each In issue at December 31, 2016 Issued: Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each Ordinary shares of 1p each In issue at December 31, 2017

Financial assets and financia42

Financial assets and financial liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Financial assets and financial liabilities
Schedule of financial assets	Financial assets at amortized cost Financial assets US $ 2017 Prepaid expenses and other receivables Cash and cash equivalents 2016 Prepaid expenses and other receivables Cash and cash equivalents
Schedule of financial liabilities	Financial liabilities at amortized cost Financial liabilities US $ 2017 Trade and other payables Payable on completion of clinical trial Derivative liabilities 2016 Trade and other payables Payable on completion of clinical trial Derivative liabilities

Subsidiaries (Tables)

Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2017
Subsidiaries
Schedule of subsidiaries	Method used Country of Percentage Percentage to account for Company name incorporation shareholding voting power investment Motif BioSciences Inc. Delaware, USA % % Consolidation

General information (Details)

General information (Details)	Nov. 15, 2017USD ($)tranche$ / sharesshares	Nov. 14, 2017£ / shares$ / sharesshares	Jun. 23, 2017USD ($)£ / sharesshares	Nov. 23, 2016£ / sharesshares	Nov. 23, 2016$ / sharesshares	Nov. 18, 2016£ / sharesshares	Nov. 18, 2016USD ($)$ / sharesshares	Jun. 30, 2017£ / sharesshares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2013USD ($)
General information
Cash | $									$ 22,651,475	$ 21,829,632	$ 28,594,347	$ 3,281
Loss for the year | $									44,810,366	40,324,302	8,516,699
Net cash used in operating activities | $									37,434,729	27,942,011	7,997,684
Term Loan | $									$ 15,000,000
Number of ordinary shares for one ADS									20
Total number of ADS warrants issued							1,219,246
Number of ADS warrants issued in alliance with ADS issuance							0.5
Underwriting discounts, commissions and offering expenses | $							$ 3,500,000		$ 1,734,562	$ 3,370,155	$ 2,898,693
Proceeds form shares issuance | $							$ 21,500,000
Percentage of equity securities							10.00%
U.S. public offering
General information
Number of ordinary shares for one ADS							20
Number of ADS warrants issued in alliance with ADS issuance							0.5
European placement
General information
Warrants exercise price						0.32	0.40
Number of warrants issued in alliance with ordinary shares issuance							0.5
Ordinary share warrant period (in years)							5 years
Ordinary shares
General information
Number of shares issued				22,863,428	22,863,428	71,633,248	71,633,248		263,519,128	195,741,528	108,601,496
Share price per share/warrant combination | £ / shares				£ 0.28
Ordinary shares | U.S. public offering
General information
Number of shares issued						48,769,820	48,769,820
Ordinary shares | European placement
General information
Number of securities called by warrants						11,431,714	11,431,714
Number of shares issued						22,863,428	22,863,428
Share price per share/warrant combination | (per share)						£ 0.28	$ 0.35
ADS
General information
Number of shares issued				2,438,491	2,438,491
Number of ordinary shares for one ADS				20	20
Share price per share/warrant combination | $ / shares					$ 6.98
ADS | U.S. public offering
General information
Number of warrants issued							1,219,246
Warrants exercise price | $ / shares							8.03
Number of shares issued						2,438,491	2,438,491
Share price per share/warrant combination | $ / shares							$ 6.98
ADS Warrant period (in years)							5 years
Ordinary shares issued, June 2017
General information
Number of shares issued			66,666,667					66,666,667
Share price | £ / shares			0.30					30
Proceeds form shares issuance | $			$ 23,681,739
Term Loan | Hercules
General information
Debt financing | $	$ 20,000,000
Number of tranches | tranche	2
Term Loan | $	$ 15,000,000
Remaining borrowing capacity | $	$ 5,000,000
Interest-only period (in months)	15 months
Capital and interest repayment period (in months)	30 months
Interest rate (as a percent)	10.00%
Share price | £ / shares		9.53
Number of ordinary shares for one ADS	20
Term Loan | Hercules | ADS
General information
Number of securities called by warrants	73,452	73,452
Exercise price of warrants | $ / shares	$ 9.53	$ 9.53
Warrants issued, in terms of loan coverage (as a percent)	3.50%	3.50%
Term Loan | Hercules | Maximum
General information
Interest-only period (in months)	21 months
Right to participate in any subsequent financing | $	$ 1,000,000

General information - Convertib

General information - Convertible Notes (Details) - USD ($)	Sep. 07, 2016	Dec. 31, 2016	Dec. 31, 2017	Nov. 23, 2016	Nov. 18, 2016	Dec. 31, 2015
Ordinary shares
Interest bearing loans and borrowings
Number of shares issued		195,741,528	263,519,128	22,863,428	71,633,248	108,601,496
Amended and restated convertible notes
Interest bearing loans and borrowings
Interest costs incurred	$ 0
Amount of outstanding principal and accrued interest of notes converted into ordinary shares		$ 3,550,786
Number of ordinary shares issued for conversion of notes		14,510,770
Conversion rate (in dollars per share)		$ 0.2447
Amphion Innovations plc | Amended and restated convertible notes | Ordinary shares
Interest bearing loans and borrowings
Number of shares issued	409,000

General information - Group reo

General information - Group reorganization (Details)	Jul. 22, 2015£ / sharesshares	Apr. 02, 2015£ / sharesshares	Dec. 31, 2017shares	Dec. 31, 2016shares	Nov. 23, 2016shares	Nov. 18, 2016shares	Dec. 31, 2015shares	Feb. 18, 2015EquityInstruments
Motif BioSciences Inc
General information
Number of shares issued to shareholders | EquityInstruments								36,726,242
Ordinary shares
General information
Number of shares issued			263,519,128	195,741,528	22,863,428	71,633,248	108,601,496
Ordinary shares | AIM
General information
Number of shares issued		14,186,140
Share price | £ / shares		0.20
Ordinary shares | Subsequent placement
General information
Number of shares issued	44,000,000
Share price | £ / shares	0.50
ADS
General information
Number of shares issued					2,438,491

General information - Acquisiti

General information - Acquisition of assets (Details)	Apr. 02, 2015shares	Dec. 31, 2017shares	Apr. 01, 2015EquityInstruments	Feb. 18, 2015EquityInstruments
Motif BioSciences Inc
General information
Number of shares issued to shareholders | EquityInstruments				36,726,242
Nuprim Inc
General information
Ordinary shares as consideration		11,318,439
Warrants issued		9,432,033
Nuprim Inc | AIM
General information
Ordinary shares as consideration	9,805,400
Warrants issued	9,432,033
Nuprim Inc | Motif BioSciences Inc
General information
Number of shares issued to shareholders | EquityInstruments			1,513,040

Significant accounting polici48

Significant accounting policies (Details)	12 Months Ended
	Dec. 31, 2017USD ($)segment
Significant accounting policies
Non-cash movement for issuance of warrants in respect of term loan	$ 419,573
Revenues	$ 0
Number of operating segments | segment	1
Hercules | Term Loan
Significant accounting policies
Cash inflow from term loan net of issuance costs	$ 14,400,000

Financial risk management - Cre

Financial risk management - Credit risk (Details) - Credit risk - Receivables	12 Months Ended
	Dec. 31, 2017USD ($)
Credit risk
Impairment	$ 0
Over three months
Credit risk
Financial assets	$ 0

Financial risk management - Liq

Financial risk management - Liquidity risk (Details) - Liquidity risk	12 Months Ended
	Dec. 31, 2017USD ($)item	Dec. 31, 2016USD ($)
Liquidity risk
Number of additional clinical trails | item	3
Financial liabilities	$ 39,445,853	$ 18,617,175
Trade and other payables
Liquidity risk
Financial liabilities	10,889,554	12,319,117
Payable on completion of clinical trial
Liquidity risk
Financial liabilities	500,000	500,000
Derivative liabilities
Liquidity risk
Financial liabilities	12,626,299	5,798,058
Term Loan
Liquidity risk
Financial liabilities	15,430,000
Less than 1 year
Liquidity risk
Financial liabilities	11,389,554	12,819,117
Less than 1 year | Trade and other payables
Liquidity risk
Financial liabilities	10,889,554	12,319,117
Less than 1 year | Payable on completion of clinical trial
Liquidity risk
Financial liabilities	500,000	500,000
Between 1 and 2 years
Liquidity risk
Financial liabilities	4,699,701
Between 1 and 2 years | Term Loan
Liquidity risk
Financial liabilities	4,699,701
Between 2 and 5 years
Liquidity risk
Financial liabilities	23,356,598	5,798,058
Between 2 and 5 years | Derivative liabilities
Liquidity risk
Financial liabilities	12,626,299	$ 5,798,058
Between 2 and 5 years | Term Loan
Liquidity risk
Financial liabilities	$ 10,730,299

Financial risk management - Mar

Financial risk management - Market risk (Details) - USD ($)	Dec. 31, 2017	Nov. 15, 2017	Dec. 31, 2016
Foreign currency risk | Sterling
Currency risk
Sterling - Cash	$ 461,857		$ 17,795
Interest rate risk | Cash and cash equivalents
Interest rate risk
Financial assets	$ 22,700,000
Hercules | Term Loan
Interest rate risk
Interest rate (as a percent)		10.00%
Hercules | Term Loan | Interest rate risk
Interest rate risk
Interest rate (as a percent)	10.00%

Other income and expense item52

Other income and expense items - Other income and Breakdown of expenses by nature (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other income and expense items
Gains on settlement of contract disputes		$ 83,320	$ 5,027
General and administrative expenses
Employee benefits expenses, including share-based payments	$ 2,778,854	1,445,110	1,146,566
Directors' fees	728,798	423,051	380,969
Legal and professional fees	2,762,334	2,073,317	1,444,507
Investor and public relations advisory fees	1,283,012	647,919	292,949
Other expenses	988,398	322,753	312,189
Total general and administrative expenses	8,541,396	4,912,150	3,577,180
Research and development costs
Employee benefits expenses, including share-based payments	1,468,719	677,412
Contract research organization expenses	22,066,179	30,445,967	3,055,421
Chemistry and manufacturing development and other non-clinical development	2,933,475	2,145,641	949,466
Other research and development costs	3,006,920	1,525,795	676,053
Total research and development costs	$ 29,475,293	$ 34,794,815	$ 4,680,940

Other income and expense item53

Other income and expense items - Auditors' Remuneration and Finance income and costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Auditors' Remuneration
Audit Fees	$ 526,170	$ 871,523	$ 73,730
Total Auditor's Remuneration	526,170	871,523	73,730
Finance income
Interest from financial assets	133,612	69,754	15,028
Total finance income	133,612	69,754	15,028
Finance costs
Interest expense	(200,000)	(383,259)	(268,216)
Accretion of end of term payment	(22,758)
Amortization of deferred financing costs	(52,691)
Total finance costs	(275,449)	(383,259)	(268,216)
Net finance costs	$ (141,837)	$ (313,505)	$ (253,188)

Employee numbers and costs (Det

Employee numbers and costs (Details)	12 Months Ended
	Dec. 31, 2017USD ($)employee	Dec. 31, 2016USD ($)employee	Dec. 31, 2015USD ($)employee
Employee numbers and costs
Monthly average number of persons employed | employee	8	6	4
Wages and salaries	$ 2,287,458	$ 1,527,776	$ 935,081
Social security and other employer costs	252,040	67,410	60,604
Share based payments	1,120,374	119,845	150,881
Short term benefits	$ 3,659,872	$ 1,715,031	$ 1,146,566
Executive
Employee numbers and costs
Monthly average number of persons employed | employee	1	2	2
Key management personnel
Employee numbers and costs
Monthly average number of persons employed | employee	7	4	2

Directors' remuneration (Detail

Directors' remuneration (Details)	Feb. 28, 2018USD ($)	Dec. 31, 2017GBP (£)$ / £director	Dec. 31, 2017USD ($)$ / £director	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Directors' remuneration
Salaries and fees			$ 1,150,116
Bonuses			127,500
Social Security			25,062
Total			$ 1,302,678	$ 1,172,119	$ 1,076,575
Number of directors exercising share options | director		0	0
Graham Lumsden
Directors' remuneration
Salaries and fees			$ 425,000
Bonuses			127,500
Social Security			15,499
Total			567,999	488,510	557,180
Amount of employer 401k pension contributions excluded in remuneration			7,950
Robert Bertoldi
Directors' remuneration
Salaries and fees			125,000
Social Security			9,563
Total			134,563	137,783	135,126
Amount of employer 401k pension contributions excluded in remuneration			6,075
Richard Morgan
Directors' remuneration
Salaries and fees			113,500
Total			113,500	177,725	217,072
Charlotta Ginman
Directors' remuneration
Salaries and fees			67,279
Total		£ 52,195	$ 67,279	57,475	32,042
Average exchange rate | $ / £		1.289	1.289
Jonathan Gold
Directors' remuneration
Salaries and fees			$ 194,004
Total			194,004	114,094	25,881
Zaki Hosny
Directors' remuneration
Salaries and fees			63,000
Total			63,000	57,475	28,756
Mary Lake Polan
Directors' remuneration
Salaries and fees			60,000
Total			60,000	54,094	25,881
John Stakes
Directors' remuneration
Total				30,869	28,756
Bruce Williams
Directors' remuneration
Salaries and fees			64,000
Total			64,000	$ 54,094	$ 25,881
Craig T. Albanese
Directors' remuneration
Salaries and fees			38,333
Total			$ 38,333
Forecast | Graham Lumsden
Directors' remuneration
Bonus amount awarded	$ 127,500
Forecast | Graham Lumsden | Bonus contingent liability
Directors' remuneration
Contingent amount	$ 42,500

Directors' remuneration - Right

Directors' remuneration - Rights to subscribe for shares (Details)	12 Months Ended
	Dec. 31, 2017USD ($)OptionsOption	Dec. 31, 2016OptionsOption
Directors' remuneration
Outstanding at the beginning of the year (in shares) | Option	15,563,182	13,427,495
Granted (in shares) | Option	5,800,000	3,261,577
Outstanding at the end of the year (in shares) | Option	17,065,534	15,563,182
Exercise price (in dollars per share) | $	$ 0.34
Richard Morgan
Directors' remuneration
Outstanding at the beginning of the year (in shares)	582,344
Outstanding at the end of the year (in shares)	582,344	582,344
Richard Morgan | Granted on January 1, 2010
Directors' remuneration
Outstanding at the beginning of the year (in shares)	73,215
Outstanding at the end of the year (in shares)	73,215	73,215
Exercise price (in dollars per share) | $	$ 0.70
Richard Morgan | Granted on January 1, 2011
Directors' remuneration
Outstanding at the beginning of the year (in shares)	6,179
Outstanding at the end of the year (in shares)	6,179	6,179
Exercise price (in dollars per share) | $	$ 0.70
Richard Morgan | Granted on December 4, 2014
Directors' remuneration
Outstanding at the beginning of the year (in shares)	502,950
Outstanding at the end of the year (in shares)	502,950	502,950
Exercise price (in dollars per share) | $	$ 0.14
Craig T. Albanese
Directors' remuneration
Granted (in shares)	100,000
Outstanding at the end of the year (in shares)	100,000
Craig T. Albanese | Granted on May 4, 2017
Directors' remuneration
Granted (in shares)	100,000
Outstanding at the end of the year (in shares)	100,000
Exercise price (in dollars per share) | $	$ 0.44
Robert Bertoldi
Directors' remuneration
Outstanding at the beginning of the year (in shares)	305,362
Outstanding at the end of the year (in shares)	305,362	305,362
Robert Bertoldi | Granted on January 1, 2010
Directors' remuneration
Outstanding at the beginning of the year (in shares)	53,887
Outstanding at the end of the year (in shares)	53,887	53,887
Exercise price (in dollars per share) | $	$ 0.70
Robert Bertoldi | Granted on December 4, 2014
Directors' remuneration
Outstanding at the beginning of the year (in shares)	251,475
Outstanding at the end of the year (in shares)	251,475	251,475
Exercise price (in dollars per share) | $	$ 0.14
Charlotta Ginman
Directors' remuneration
Outstanding at the beginning of the year (in shares)	251,475
Outstanding at the end of the year (in shares)	251,475	251,475
Charlotta Ginman | Granted on December 4, 2014
Directors' remuneration
Outstanding at the beginning of the year (in shares)	251,475
Outstanding at the end of the year (in shares)	251,475	251,475
Exercise price (in dollars per share) | $	$ 0.14
Jonathan Gold
Directors' remuneration
Outstanding at the beginning of the year (in shares)	330,941
Outstanding at the end of the year (in shares)	330,941	330,941
Jonathan Gold | Granted on January 1, 2010
Directors' remuneration
Outstanding at the beginning of the year (in shares)	73,502
Outstanding at the end of the year (in shares)	73,502	73,502
Exercise price (in dollars per share) | $	$ 0.70
Jonathan Gold | Granted on January 1, 2011
Directors' remuneration
Outstanding at the beginning of the year (in shares)	5,964
Outstanding at the end of the year (in shares)	5,964	5,964
Exercise price (in dollars per share) | $	$ 0.70
Jonathan Gold | Granted on December 4, 2014
Directors' remuneration
Outstanding at the beginning of the year (in shares)	251,475
Outstanding at the end of the year (in shares)	251,475	251,475
Exercise price (in dollars per share) | $	$ 0.14
Zaki Hosny
Directors' remuneration
Outstanding at the beginning of the year (in shares)	430,094
Outstanding at the end of the year (in shares)	430,094	430,094
Zaki Hosny | Granted on June 18, 2009
Directors' remuneration
Outstanding at the beginning of the year (in shares)	53,888
Outstanding at the end of the year (in shares)	53,888	53,888
Exercise price (in dollars per share) | $	$ 0.70
Zaki Hosny | Granted on January 1, 2010
Directors' remuneration
Outstanding at the beginning of the year (in shares)	14,370
Outstanding at the end of the year (in shares)	14,370	14,370
Exercise price (in dollars per share) | $	$ 0.70
Zaki Hosny | Granted on January 1, 2011
Directors' remuneration
Outstanding at the beginning of the year (in shares)	2,587
Outstanding at the end of the year (in shares)	2,587	2,587
Exercise price (in dollars per share) | $	$ 0.70
Zaki Hosny | Granted on January 30, 2013
Directors' remuneration
Outstanding at the beginning of the year (in shares)	107,774
Outstanding at the end of the year (in shares)	107,774	107,774
Exercise price (in dollars per share) | $	$ 0.14
Zaki Hosny | Granted on December 4, 2014
Directors' remuneration
Outstanding at the beginning of the year (in shares)	251,475
Outstanding at the end of the year (in shares)	251,475	251,475
Exercise price (in dollars per share) | $	$ 0.14
Graham Lumsden
Directors' remuneration
Outstanding at the beginning of the year (in shares)	3,448,800
Granted (in shares)	1,700,000
Outstanding at the end of the year (in shares)	5,148,800	3,448,800
Graham Lumsden | Granted on May 25, 2013
Directors' remuneration
Outstanding at the beginning of the year (in shares)	574,800
Outstanding at the end of the year (in shares)	574,800	574,800
Exercise price (in dollars per share) | $	$ 0.14
Graham Lumsden | Granted on December 4, 2014
Directors' remuneration
Outstanding at the beginning of the year (in shares)	2,874,000
Outstanding at the end of the year (in shares)	2,874,000	2,874,000
Exercise price (in dollars per share) | $	$ 0.14
Graham Lumsden | Granted on February 7, 2017
Directors' remuneration
Granted (in shares)	1,000,000
Outstanding at the end of the year (in shares)	1,000,000
Exercise price (in dollars per share) | $	$ 0.33
Graham Lumsden | Granted on February 7, 2017
Directors' remuneration
Granted (in shares)	700,000
Outstanding at the end of the year (in shares)	700,000
Exercise price (in dollars per share) | $	$ 0.33
Mary Lake Polan
Directors' remuneration
Outstanding at the beginning of the year (in shares)	323,971
Outstanding at the end of the year (in shares)	323,971	323,971
Mary Lake Polan | Granted on January 1, 2010
Directors' remuneration
Outstanding at the beginning of the year (in shares)	67,036
Outstanding at the end of the year (in shares)	67,036	67,036
Exercise price (in dollars per share) | $	$ 0.70
Mary Lake Polan | Granted on January 1, 2011
Directors' remuneration
Outstanding at the beginning of the year (in shares)	5,461
Outstanding at the end of the year (in shares)	5,461	5,461
Exercise price (in dollars per share) | $	$ 0.70
Mary Lake Polan | Granted on December 4, 2014
Directors' remuneration
Outstanding at the beginning of the year (in shares)	251,474
Outstanding at the end of the year (in shares)	251,474	251,474
Exercise price (in dollars per share) | $	$ 0.14
Bruce Williams
Directors' remuneration
Outstanding at the beginning of the year (in shares)	422,118
Outstanding at the end of the year (in shares)	422,118	422,118
Bruce Williams | Granted on January 1, 2010
Directors' remuneration
Outstanding at the beginning of the year (in shares)	67,252
Outstanding at the end of the year (in shares)	67,252	67,252
Exercise price (in dollars per share) | $	$ 0.70
Bruce Williams | Granted on January 16, 2010
Directors' remuneration
Outstanding at the beginning of the year (in shares)	28,740
Outstanding at the end of the year (in shares)	28,740	28,740
Exercise price (in dollars per share) | $	$ 0.70
Bruce Williams | Granted on November 15, 2010
Directors' remuneration
Outstanding at the beginning of the year (in shares)	71,850
Outstanding at the end of the year (in shares)	71,850	71,850
Exercise price (in dollars per share) | $	$ 0.70
Bruce Williams | Granted on January 1, 2011
Directors' remuneration
Outstanding at the beginning of the year (in shares)	2,802
Outstanding at the end of the year (in shares)	2,802	2,802
Exercise price (in dollars per share) | $	$ 0.70
Bruce Williams | Granted on December 4, 2014
Directors' remuneration
Outstanding at the beginning of the year (in shares)	251,474
Outstanding at the end of the year (in shares)	251,474	251,474
Exercise price (in dollars per share) | $	$ 0.14

Income tax expense (Details)

Income tax expense (Details) - USD ($)	Apr. 01, 2015	Mar. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income tax expense
Current tax expense			$ 22,000	$ 287	$ 774
U.K. corporation tax rate	19.00%	21.00%	19.00%	19.00%	19.00%
Loss on ordinary activities before taxation			$ (44,788,366)	$ (40,324,015)	$ (8,515,925)
U.K. Corporation tax at 19%			(1,570,723)	(449,929)	(355,889)
Overseas tax at higher rate			(7,669,495)	(12,954,729)	(2,297,873)
Effects of:
Unrecognized losses			(9,240,218)	(13,404,371)	(2,652,988)
Other adjustments-overseas taxes			22,000	287	774
Total tax charge			22,000	287	774
U.K.
Income tax expense
Unrecognized cumulative deferred tax asset			1,783,102	1,783,102
Loss on ordinary activities before taxation			(10,488,833)	(10,488,833)
Overseas taxes
Income tax expense
Current tax expense			$ 22,000	$ 287	$ 774

Loss per share (Details)

Loss per share (Details) - USD ($)		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Loss per share
Loss after taxation		$ (44,810,366)	$ (40,324,302)	$ (8,516,699)
Weighted average number of ordinary shares, diluted		231,530,091	116,558,191	61,225,922
Basic and diluted loss per share	[1]	$ (0.19)	$ (0.35)	$ (0.14)
Potentially dilutive securities excluded from the computation of diluted weighted average shares outstanding		66,465,481	12,536,721	28,619,406
Convertible promissory notes
Loss per share
Potentially dilutive securities excluded from the computation of diluted weighted average shares outstanding				14,510,770
Warrants
Loss per share
Potentially dilutive securities excluded from the computation of diluted weighted average shares outstanding		49,399,947	5,726,364	6,925,962
Share options
Loss per share
Potentially dilutive securities excluded from the computation of diluted weighted average shares outstanding		17,065,534	6,810,357	7,182,674
[1]	In accordance with IAS 33 “Earnings per share”, shares are not diluted where the entity has reported a loss for the period.

Intangible assets (Details)

Intangible assets (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Intangible assets
Intangible assets	$ 6,195,748	$ 6,195,748
Changes in intangible assets
Intangible assets other than goodwill at beginning of period	6,195,748	6,195,748
Intangible assets other than goodwill at end of period	6,195,748	6,195,748
Cost
Intangible assets
Intangible assets	6,195,748	6,195,748
Changes in intangible assets
Intangible assets other than goodwill at beginning of period	$ 6,195,748	6,195,748
Intangible assets other than goodwill at end of period		$ 6,195,748

Intangible assets - Acquisition

Intangible assets - Acquisition of exclusive rights (Details) - Nuprim Inc	12 Months Ended
	Dec. 31, 2017USD ($)£ / shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)
Intangible assets
Ordinary shares as consideration | shares		11,318,439
Ordinary shares as consideration (per share) | £ / shares	£ 0.20
Warrants issued | shares		9,432,033
Warrants issued (per share) | £ / shares	£ 0.20
Discount	£ 0	$ 0
Purchase consideration:
Ordinary shares in Motif Bio plc	3,355,375	3,355,375
Warrants to subscribe for ordinary shares in Motif Bio plc	2,340,373	2,340,373
Total purchase consideration	5,695,748	5,695,748
Iclaprim assets	6,195,748	6,195,748
Milestone payment	(500,000)	(500,000)
Net assets acquired	£ 5,695,748	5,695,748
Amortisation expense		0
Impairment loss		$ 0	$ 0

Prepaid expenses and other re61

Prepaid expenses and other receivables (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Prepaid expenses and other receivables
Prepayments and other receivables	$ 317,584	$ 401,064
Collateral held as security	$ 0

Cash and cash equivalents (Deta

Cash and cash equivalents (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2013
Cash and cash equivalents
Cash at bank	$ 22,651,475	$ 21,829,632
Cash and cash equivalents	$ 22,651,475	$ 21,829,632	$ 28,594,347	$ 3,281

Trade and other payables (Detai

Trade and other payables (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Trade and other payables
Trade payables	$ 6,464,038	$ 734,405
Amounts due to affiliates		78
Other payable	124,244	2,156
Trade and other payables	10,889,554	12,319,117
Contract research organization
Trade and other payables
Trade payables	5,704,052
Accrued expenses	1,293,379	10,854,531
Other
Trade and other payables
Accrued expenses	$ 3,007,893	$ 727,947

Interest bearing loans and bo64

Interest bearing loans and borrowings (Details)	Nov. 15, 2017USD ($)tranche$ / sharesshares	Nov. 14, 2017$ / sharesshares	Nov. 23, 2016shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Interest bearing loans and borrowings
Term Loan				$ 15,000,000
Deferred financing costs				(942,853)
Net non-current liabilities				$ 14,057,147
Number of ordinary shares for one ADS | shares				20
Interest expense				$ 275,449	$ 383,259	$ 268,216
Cash interest expense				200,000	$ 383,259	$ 268,216
Accretion expense				22,758
Amortization expense				$ 52,691
ADS
Interest bearing loans and borrowings
Number of ordinary shares for one ADS | shares			20
Term Loan | Hercules
Interest bearing loans and borrowings
Term Loan	$ 15,000,000
Debt financing	$ 20,000,000
Number of tranches | tranche	2
Remaining borrowing capacity	$ 5,000,000
Interest-only period (in months)	15 months
Capital and interest repayment period (in months)	30 months
Interest rate (as a percent)	10.00%
Payment due at end of term loan	$ 400,000
Total loan capacity subject to a term charge (as a percent)				2.15%
Number of ordinary shares for one ADS | shares	20
Fees incurred in connection with warrants				$ 500,000
Fair value of warrants issued				400,000
Interest expense				275,449
Cash interest expense				200,000
Accretion expense				22,758
Amortization expense				$ 52,691
Term Loan | Hercules | Maximum
Interest bearing loans and borrowings
Interest-only period (in months)	21 months
Right to participate in any subsequent financing	$ 1,000,000
Term Loan | ADS | Hercules
Interest bearing loans and borrowings
Number of securities called by a warrant | shares	73,452	73,452
Exercise price of warrants | $ / shares	$ 9.53	$ 9.53
Warrants issued, in terms of loan coverage (as a percent)	3.50%	3.50%

Warrants - Warrant activity (De

Warrants - Warrant activity (Details)	12 Months Ended
	Dec. 31, 2017GBP (£)EquityInstrumentsshares	Dec. 31, 2017USD ($)EquityInstrumentsshares	Dec. 31, 2017USD ($)EquityInstrumentsshares	Dec. 31, 2016GBP (£)	Dec. 31, 2016USD ($)
Warrants
Number of shares per each American Depository Share | shares	20	20
ADS warrants
Number of Warrants
Outstanding as of January 1, 2017	1,219,246	1,219,246
Granted	133,452	133,452
Exercised	(16,344)	(16,344)
Outstanding as of December 31, 2017	1,336,354	1,336,354
Weighted Average Exercise Price
Outstanding as of January 1, 2017 | $		$ 8.03
Granted | $		8.51
Exercised | $		8.03
Outstanding as of December 31, 2017 | $		$ 8.08
Ordinary shares classified as liability | shares	1,336,354		1,336,354
Exercise Price | $			$ 7.91		$ 8.03
ADS Expiration November 23, 2021
Weighted Average Exercise Price
Number Outstanding and Exercisable (in shares)	1,202,902		1,202,902
Exercise Price | $			$ 8.03
ADS Expiration July 31, 2022
Weighted Average Exercise Price
Number Outstanding and Exercisable (in shares)	60,000		60,000
Exercise Price | $			$ 7.26
ADS Expiration November 14, 2022
Weighted Average Exercise Price
Number Outstanding and Exercisable (in shares)	73,452		73,452
Exercise Price | $			$ 9.53
Ordinary warrants
Number of Warrants
Outstanding as of January 1, 2017	23,729,865	23,729,865
Expired	(416,645)	(416,645)
Exercised	(640,353)	(640,353)
Outstanding as of December 31, 2017	22,672,867	22,672,867
Weighted Average Exercise Price
Outstanding as of January 1, 2017 | £	£ 0.278
Expired | $		$ 0.56
Exercised | £	0.322
Outstanding as of December 31, 2017 | £	£ 0.272
Ordinary shares classified as liability | shares	10,791,361		10,791,361
Exercise Price | £	£ 0.322			£ 0.322
Ordinary Shares Expiration April 2, 2020
Weighted Average Exercise Price
Number Outstanding and Exercisable (in shares)	1,367,089		1,367,089
Exercise Price | £	£ 0.20
Ordinary Shares Expiration July 21, 2020
Weighted Average Exercise Price
Number Outstanding and Exercisable (in shares)	1,082,384		1,082,384
Exercise Price | £	£ 0.50
Ordinary Shares Expiration November 23, 2021
Weighted Average Exercise Price
Number Outstanding and Exercisable (in shares)	10,791,361		10,791,361
Exercise Price | £	£ 0.322
Ordinary Shares Expiration April 2, 2025
Weighted Average Exercise Price
Number Outstanding and Exercisable (in shares)	9,432,033		9,432,033
Exercise Price | £	£ 0.20
Ordinary Shares Expiration between April 2, 2020 and April 2, 2025
Weighted Average Exercise Price
Ordinary shares classified as equity | shares	11,881,506		11,881,506

Warrants - Liability classified

Warrants - Liability classified warrants (Details)	Nov. 15, 2017$ / sharesshares	Nov. 14, 2017USD ($)£ / shares$ / sharesshares	Aug. 01, 2017USD ($)$ / sharesshares	Nov. 23, 2016USD ($)£ / sharesshares	Nov. 23, 2016USD ($)$ / sharesshares	Dec. 31, 2017USD ($)£ / shares$ / sharesshares	Dec. 31, 2016USD ($)£ / shares$ / shares	Dec. 31, 2017GBP (£)shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016GBP (£)shares	Dec. 31, 2016USD ($)shares	Nov. 18, 2016shares	Dec. 31, 2015shares
Warrants
Number of ordinary shares for one ADS						20
Derivative liabilities | $									$ 12,626,299		$ 5,798,058
Ordinary shares
Warrants
Number of shares issued				22,863,428	22,863,428			263,519,128	263,519,128	195,741,528	195,741,528	71,633,248	108,601,496
Share price per share/warrant combination | £ / shares				£ 0.28
ADS
Warrants
Number of shares issued				2,438,491	2,438,491
Share price per share/warrant combination | $ / shares					$ 6.98
Number of ordinary shares for one ADS				20	20
ADS warrants
Warrants
Number of warrants issued				1,219,246	1,219,246
Warrants exercise price | $ / shares					8.03
Derivative liabilities | $				£ 3,849,160	$ 3,849,160
Fair value of derivative liability | $						$ 8,927,252	$ 3,967,189
Share price | $ / shares						10.81	6.19
Exercise price | $									$ 7.91		$ 8.03
Expected volatility						74.00%	70.00%
Number of periods to exercise						3.82	4.92
Risk free rate						1.93%	1.91%
Performance warrant
Warrants
Exercise price of warrants | $ / shares			$ 7.26
Number of securities called by warrants			60,000
Number of warrants vested at the time of issuance			5,000
Number of warrants vested upon satisfying performance conditions			55,000
Derivative liabilities | $			$ 109,431
Share price | $ / shares			7.26
Exercise price | $			$ 7.26
Expected volatility			70.00%
Number of periods to exercise			5
Risk free rate			1.80%
Ordinary warrants
Warrants
Number of warrants issued				11,431,714	11,431,714
Warrants exercise price | £ / shares				0.322
Derivative liabilities | $				£ 1,812,959	$ 1,812,959
Fair value of derivative liability | $						$ 3,699,047	$ 1,830,869
Share price | £ / shares						0.41	0.25
Exercise price | £								£ 0.322		£ 0.322
Expected volatility						76.00%	70.00%
Number of periods to exercise						3.90	4.92
Risk free rate						2.09%	1.91%
Term Loan | Hercules
Warrants
Number of ordinary shares for one ADS	20
Derivative liabilities | $		$ 419,573
Share price | £ / shares		9.53
Exercise price | $		$ 9.53
Expected volatility		72.00%
Number of periods to exercise		5
Risk free rate		2.06%
Term Loan | Hercules | ADS
Warrants
Warrants issued, in terms of loan coverage (as a percent)	3.50%	3.50%
Exercise price of warrants | $ / shares	$ 9.53	$ 9.53
Number of securities called by warrants	73,452	73,452

Warrants - Liability classifi67

Warrants - Liability classified warrant activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Warrants
Balance at beginning of the period	$ 5,798,058
Issued during the year	529,004	$ 5,662,119
Exercised during the year	(284,402)
Impact of foreign exchange	192,088
Loss from revaluation of derivative liabilities	6,391,551	135,939
Balance at end of the period	$ 12,626,299	$ 5,798,058

Contingent liabilities (Details

Contingent liabilities (Details) - Forecast	Feb. 28, 2018USD ($)
Graham Lumsden
Contingent liabilities
Bonus amount awarded	$ 127,500
Graham Lumsden | Bonus contingent liability
Contingent liabilities
Separate supplemental bonus	50,000
Contingent amount	42,500
Dr. Huang
Contingent liabilities
Bonus amount awarded	142,000
Dr. Huang | Bonus contingent liability
Contingent liabilities
Contingent amount	$ 42,000

Share based payments - Share Op

Share based payments - Share Option Plan (Details)	Apr. 01, 2015Options	Dec. 31, 2017USD ($)OptionY	Dec. 31, 2016USD ($)OptionY
Number and weighted average exercise prices of share options
Outstanding at the beginning of the year (in shares) | Option		15,563,182	13,427,495
Granted (in shares) | Option		5,800,000	3,261,577
Forfeited during the year (in shares) | Option		(4,153,948)
Exercised during the year (in shares) | Option		(143,700)	(263,690)
Expired during the year (in shares) | Option			(862,200)
Outstanding at the end of the year (in shares) | Option		17,065,534	15,563,182
Outstanding at the beginning of the year (in dollars)		$ 0.37	$ 0.33
Granted during the year (in dollars)		0.33	0.58
Forfeited during the year (in dollars)		0.53
Exercised during the year (in dollars)		0.14	0.14
Expired during the year (in dollars)			0.70
Outstanding at the end of the year (in dollars)		$ 0.32	$ 0.37
Number of options exercisable (in shares) | Option		11,334,173
Weighted average exercise price, exercisable (in dollars)		$ 0.29
Weighted average contractual term of options outstanding (in years) | Y		7	7.3
Weighted average remaining contractual term of options exercisable (in years)		6 years 1 month 6 days
Weighted-average fair value of options granted		$ 0.26
New Plan
Share based payments
Options exercisable | Options	0
Expiration period	10 years
Minimum
Number and weighted average exercise prices of share options
Exercise price		0.14
Maximum
Number and weighted average exercise prices of share options
Exercise price		$ 0.91

Share based payments - Weighted

Share based payments - Weighted-average assumptions (Details)	12 Months Ended
	Dec. 31, 2017USD ($)Y
Share based payments
Share price	$ 0.34
Exercise price	$ 0.34
Expected volatility	70.86%
Term | Y	10
Risk free rate	2.11%

Share based payments - Stock-ba

Share based payments - Stock-based payments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share based payments
Share-based payment expense	$ 1,708,075	$ 513,541	$ 325,908
Amount of expense understated		802,282	291,696	$ 31,799
General and administrative expense
Share based payments
Share-based payment expense	1,143,496	$ 513,541	$ 325,908
Increase in expense due to out-of-period correction	762,836
Research and development expense
Share based payments
Share-based payment expense	564,579
Increase in expense due to out-of-period correction	$ 362,941

Share capital (Details)

Share capital (Details)

Jun. 23, 2017£ / sharesshares

Nov. 29, 2016USD ($)

Nov. 23, 2016£ / sharesshares

Nov. 23, 2016USD ($)$ / sharesshares

Sep. 09, 2016USD ($)

Nov. 30, 2017USD ($)

Jul. 31, 2017USD ($)

Jun. 30, 2017USD ($)£ / shares

May 31, 2017USD ($)

Jan. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2017USD ($)shares

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)shares

Nov. 30, 2017£ / sharesshares

Jul. 31, 2017£ / sharesshares

Jun. 30, 2017£ / sharesshares

May 31, 2017£ / sharesshares

Jan. 31, 2017£ / sharesshares

Dec. 31, 2016£ / shares

Dec. 31, 2016USD ($)$ / sharesshares

Nov. 29, 2016£ / sharesshares

Nov. 18, 2016shares

Sep. 09, 2016£ / sharesshares

Shares issued

Shares issued (in value) | $

$ 3,589,201

$ 2,728,199

Shares issued during the period (in value) | $

$ 25,416,301

$ 19,599,378

$ 42,430,045

Number of ordinary shares for one ADS

20

Ordinary shares

Shares issued

Number of shares issued

22,863,428

263,519,128

108,601,496

195,741,528

71,633,248

Shares issued (in value) | $

$ 3,589,201

$ 1,645,291

$ 2,728,199

Share price per share/warrant combination | £ / shares

£ 0.28

Ordinary shares issued, September 9, 2016 | Amphion Innovations plc

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

409,000

Shares issued during the period (in value) | $

$ 5,405

American depository shares issued, November 23, 2016

Shares issued

Number of shares issued

2,438,491

Number of warrants issued

1,219,246

Share price per share/warrant combination | $ / shares

$ 6.98

Number of ordinary shares for one ADS

20

Ordinary shares issued, November 23, 2016

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

22,863,428

Shares issued during the period (in value) | $

$ 284,833

Number of warrants issued

11,431,714

Share price per share/warrant combination | £ / shares

£ 0.28

Ordinary shares issued, November 18, 2016

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

48,769,820

Shares issued during the period (in value) | $

$ 607,574

Ordinary shares issued, November 29, 2016

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

119,990

Shares issued during the period (in value) | $

$ 1,509

Ordinary shares issued, December 2016

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

467,024

Shares issued during the period (in value) | $

$ 5,801

Ordinary shares issued upon conversion, December 2016 | Amphion Innovations plc and Amphion Innovations US Inc

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

14,510,770

Shares issued during the period (in value) | $

177,786

Amount of outstanding principal and accrued interest of notes converted into ordinary shares | $

$ 3,550,786

Conversion rate (in dollars per share) | $ / shares

$ 0.2447

Ordinary shares issued, January 2017

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

143,700

Shares issued during the period (in value) | $

$ 1,748

Ordinary shares issued, May 2017

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

326,880

Shares issued during the period (in value) | $

$ 4,262

Ordinary shares issued, June 2017

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

66,666,667

66,666,667

Shares issued during the period (in value) | $

$ 846,667

Share price | £ / shares

0.30

30

Ordinary shares issued, July 2017

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

250,000

Shares issued during the period (in value) | $

$ 3,185

Ordinary shares issued, November 2017

Shares issued

Par value per share | £ / shares

£ 1

Number of shares issued

390,353

Shares issued during the period (in value) | $

$ 5,140

Financial assets and financia73

Financial assets and financial liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Financial liabilities at amortized cost
Financial assets and financial liabilities
Financial liabilities	$ 24,015,853	$ 18,617,175
Financial assets at amortized cost
Financial assets and financial liabilities
Financial assets	22,969,059	22,230,696
Financial assets at amortized cost | Prepaid expenses and other receivables
Financial assets and financial liabilities
Financial assets	317,584	401,064
Financial assets at amortized cost | Cash and cash equivalents
Financial assets and financial liabilities
Financial assets	22,651,475	21,829,632
Trade and other payables | Financial liabilities at amortized cost
Financial assets and financial liabilities
Financial liabilities	10,889,554	12,319,117
Payable on completion of clinical trial | Financial liabilities at amortized cost
Financial assets and financial liabilities
Financial liabilities	500,000	500,000
Derivative liabilities | Financial liabilities at amortized cost
Financial assets and financial liabilities
Financial liabilities	$ 12,626,299	$ 5,798,058

Financial assets and financia74

Financial assets and financial liabilities - Transfers of fair value (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Financial assets and financial liabilities
Transfer of financial assets fair value from Level 1 to Level 2	$ 0	$ 0
Transfer of financial assets fair value from Level 2 to Level 1	0	0
Financial assets fair value transfer into Level 3	0	0
Financial assets fair value transfer out of Level 3	0	0
Transfer of financial liabilities fair value from Level 1 to Level 2	0	0
Transfer of financial liabilities fair value from Level 2 to Level 1	0	0
Financial liabilities fair value transfer into Level 3	0	0
Financial liabilities fair value transfer out of Level 3	$ 0	$ 0

Subsidiaries (Details)

Subsidiaries (Details) - Motif BioSciences Inc	12 Months Ended
	Dec. 31, 2017
Subsidiaries
Percentage shareholding	100.00%
Percentage voting power	100.00%

Related party transactions (Det

Related party transactions (Details)	Dec. 31, 2017
Amphion Group
Directors' remuneration
Ordinary shares held by the related parties (in percentage)	14.48%

Related party transactions - Ag

Related party transactions - Agreements (Details) - USD ($)	Apr. 07, 2017	Sep. 07, 2016	Jul. 01, 2016	Apr. 13, 2016	Nov. 01, 2015	Apr. 01, 2015	Dec. 31, 2017	Jul. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Advisory and Consultancy Agreement | Amphion Innovations US Inc
Directors' remuneration
Consideration for services										$ 120,000	$ 120,000
Annual consideration for services						$ 120,000
Advance written notice period for termination of agreement (in days)									90 days
Consultancy Agreement | Amphion Innovations US Inc
Directors' remuneration
Consideration for services										170,500	19,633
Monthly consideration for services		$ 15,500
Initial agreement term (in months)		12 months
Consultancy Agreement | Amphion Innovations plc
Directors' remuneration
Consideration for services										$ 125,000	$ 127,500
Annual consideration for services			$ 75,000		$ 180,000			$ 125,000
Written notice period for renewal of agreement(in days)						90 days
Monthly consideration for services						$ 5,000
Initial agreement term (in months)						12 months
Advance written notice period for termination of agreement (in days)							90 days
Consultancy Agreement | Jonathan Gold
Directors' remuneration
Monthly consideration for services	$ 16,167			$ 10,000
Initial agreement term (in months)	12 months			6 months
Consultancy Agreement | Jonathan Gold | Maximum
Directors' remuneration
Advance written notice period for termination of agreement (in days)				30 days
Consultancy Agreement | Jonathan Gold | Minimum
Directors' remuneration
Advance written notice period for termination of agreement (in days)	30 days

Subsequent events (Details)

Subsequent events (Details) - USD ($) $ in Millions	Apr. 03, 2018	Jan. 31, 2018	Dec. 31, 2017
Subsequent events
Number of ordinary shares for one ADS			20
Major ordinary share transactions
Subsequent events
Duration shelf registration will remain effective		3 years
Number of shares offered to sell		$ 80
Number of ordinary shares for one ADS		20
Initiating the submission of NDA
Subsequent events
Application fee not required to pay	$ 2.4